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Abstract 
 Diabetes is a risk factor for stroke and vascular dementia.  Clinical studies using 
gadolinium-magnetic resonance imaging techniques have shown diabetic patients exhibit a 
permeability increase at the blood-brain barrier (BBB) (Starr et al, 2003).  The BBB, a 
vascular interface at the level of brain microvascular vessels, functions to provide nutrients 
and oxygen from the peripheral circulation, mediates waste efflux from the brain, and 
protects the brain from toxins.  These functions are due to the presence of tight junction 
proteins.  Animal studies have shown increased BBB permeability is due to a decrease in 
these proteins (Hawkins et al, 2007).  Based on these studies and using the streptozotocin 
(STZ) model of diabetes, I hypothesized that the permeability and molecular changes can 
be attenuated by minocycline, a tetracycline known to cross the BBB.  STZ animals treated 
with minocycline exhibited a decrease in permeability and an increase in the tight junction 
protein, claudin-5.  Previous studies have shown that the pro-angiogenic and permeability 
cytokine, vascular endothelial growth factor (VEGF), is able to influence claudin-5 
expression (Argaw et al, 2009).  Therefore, VEGF may be involved in a minocycline-
induced increase in claudin-5 expression.  VEGF significantly increased in STZ animals with 
minocycline treatment.  Additionally, there was a significant increase in expression of the 
VEGF receptor, Flt-1, of control animals treated with minocycline, and a similar trend in 
minocycline-treated STZ animals.  However, there were no changes in the other VEGF 
receptors.  Based on these results, I hypothesized that VEGF might exert its effects on the 
BBB in diabetes.  Although there were no changes in VEGF, there was a glucose-
dependent change in PLCγ, a downstream signaling molecule involved in proliferation, 
which might help explain the permeability change observed in diabetes. 
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Chapter 1:  Introduction 
Diabetes 
Diabetes mellitus is a metabolic disorder that is characterized by hyperglycemia.  
It is generally classified into two types:  Type I (T1D) and Type II (T2D).  T1D is typically 
diagnosed in children and young adults and is due to auto-immune destruction of the 
beta cells of the pancreas.  Thus, no insulin is produced, and patients with this disease 
are insulin-dependent via injections or a pump.  The other pancreatic islets that secrete 
glucagon, somatostatin, and pancreatic polypeptide remain intact.  The symptoms of 
T1D are increased thirst, urination, hunger and weight loss.  Additionally, ketoacidosis 
and dyslipidemia may be present.  Ketoacidosis is due to reduced insulin levels, 
decreased glucose use, and an increase in gluconeogenesis (Trachtenbarg, 2005).  
Insulin deficiency leads to uncontrolled beta-oxidation of free fatty acids, which are 
converted to ketone bodies by the liver.  Poorly controlled T1D can lead to 
hypertriglyceridemia and reduced HDL, but insulin therapy can alleviate these 
abnormalities (Goldberg, 2001).   T1D has a genetic component; however, 
environmental factors could be involved in the pathogenesis of the disease.  Others 
have proposed that T1D is triggered by a virus, perhaps Coxsackie or rubella viruses 
(Alba et al., 2005).  
T2D is characterized by insulin resistance and over time an insufficient 
production of insulin.  Patients with T2D exhibit similar symptoms to those with type I 
diabetes.  The development of T2D is likely a combination of genetic factors and 
lifestyle habits.  T2D is associated with poor lifestyle habits such as lack of exercise and 
poor diet.  Patients develop insulin resistance, which is the inability to utilize insulin at 
normal levels.  Additionally, the liver, which normally stores glucose as glycogen, will 
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release abnormal amounts of glucose into the blood.  Elevated triglycerides, low HDL-C, 
and LDL-C are evident in T2D (Kumar and Singh, 2010).   Skeletal muscle, a target 
tissue for glucose uptake, becomes insulin resistant (Olefsky and Nolan, 1995).   
Management of T2D has been focused on lifestyle changes such as incorporating diet 
and exercise into routine, lowering cardiovascular risks, and managing glucose levels 
within normal range.  Treatment for T2D typically involves anti-diabetic medications 
such as metformin, sulfonylureas, and thiazolidinediones. The glucose-lowering effect of 
metformin is due to its ability to reduce hepatic glucose production and increase 
peripheral glucose uptake (Bailey et al., 1996).  Sulfonylureas bind to a receptor that is 
a component of the ATP-sensitive K+ channel in the beta cell.  Upon binding, the ATP-
sensitive K+ channels close, which will lead to increased insulin secretion.  
Thiazolidinediones are ligands for peroxisome-proliferator-activated receptor γ (PPARγ), 
a nuclear transcription factor found in adipose tissue.   PPARγ is important for adipocyte 
differentiation, proliferation, fatty acid uptake, and storage.  Thiazolidinediones act by 
promoting the fatty acid uptake and storage (Yki-Järvinen, 2004).  Insulin treatment may 
be required as well. 
Worldwide, diabetes affects approximately 171 million people, and this number is 
likely to increase to about 336 million by 2030 (Wild et al., 2004).  According to the 
National Diabetes Data Sheet compiled by the Centers of Disease Control and 
Prevention (2011), 25.8 million people, or 8.3% of the population in the United States, is 
affected by diabetes.  The American Diabetes Association reports that diabetes is the 
seventh leading cause of death but is likely to be underreported as a cause of death.  
The cost of diabetes is staggering with a total of $174 billion, of which $116 billion is due 
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to direct costs and $58 billion due to indirect costs such as disability, work loss, and 
premature mortality (Centers of Disease Control and Prevention, 2011).   Moreover, the 
American Diabetes Association estimates that the total cost increases to $218 billion 
when factoring undiagnosed diabetes, prediabetes, and gestational diabetes. 
Diabetic complications are characterized by changes in the macro- and 
microvasculature.  Macrovascular changes in diabetes result in cardiovascular disease.  
An estimated 80% of diabetic patients die from cardiovascular disease.  Of those deaths 
about 75% result from coronary artery disease (CAD) with the remaining being due to 
cerebrovascular disease, peripheral or other macrovascular disease (Cocherri, 2007).  
Separately, CAD and diabetes are associated with endothelial dysfunction; however, 
diabetes leads to further endothelial dysfunction in patients with CAD (Keymel et al 
2011).  Diabetic patients have a greater number of coronary arteries with diffuse 
distribution of atherosclerotic lesions compared to non-diabetics, and similar 
characteristics are seen in the peripheral vasculature (Milicevic et al., 2008).   There is a 
one-to-four fold increase in stroke and stroke-related events due to diabetes (Cocherri, 
2007).   
Microvascular changes in diabetes can lead to poor wound healing, nephropathy, 
retinopathy, and neuropathy.  Hyperglycemia leads to endothelial dysfunction by 
altering endothelial production of vasoconstrictor prostaglandins and affects endothelial 
cell matrix production leading to the thickening of the basement membrane (Hsueh and 
Anderson, 1992).  Poor wound healing in diabetes is due to a host of factors, including 
impaired or decreased growth factor production and angiogenic response (Brem and 
Tomic-Canic, 2007).  The angiogenic response is decreased because of reduced 
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vascular endothelial growth factor (VEGF) and stromal-derived growth factor-1α (SDF-
1α).  VEGF induces activation of endothelial nitric oxide synthase (eNOS), resulting in 
increased NO levels.  NO triggers the mobilization of bone marrow endothelial 
progenitor cells into circulation.   SDF-1α causes these cells to move to the site of injury 
(Brem and Tomic-Canic, 2007).  Changes in the renal vasculature occur in diabetes 
with increased glomerular capillary growth in the early stages of the disease.  
Hyperglycermia is believed to induce protein kinase C and increase advanced glycation 
end-products that can lead to microvascular changes (Guo et al., 2005).  Diabetic 
retinopathy constitutes a host of symptoms, including microaneurysms that will 
eventually lead to macular edema, ischemic changes, microvascular abnormalities, and 
proliferative changes (Antonetti et al., 2012).  Diabetes can contribute to various 
neuropathies, such as abnormal sensation and pain (Obrosova, 2009).    Cognitive 
impairment occurs because of inflammation in the brain, affecting the blood vessels and 
causing atrophy of brain tissue (Novak et al., 2011).  Additionally, diabetes has also 
been linked to the development of Alzheimer’s disease with both diseases having 
overlapping features such as poor glycemic control and impaired insulin function 
(Moreira et al., 2007).   Insulin signaling is believed to be involved in generation of Aβ 
peptides as well as limiting its degradation.  Furthermore, decreased glucose 
metabolism has been observed, which includes decreased enzyme activity (Moreira et 
al., 2007).  Diabetes is also an independent risk factor for stroke and vascular 
dementias (Abbott et al., 1987), and changes in the blood-brain barrier may play a part 
in these disease processes.    
 
5 
 
Blood-brain barrier (BBB) 
The brain is at the center of the central nervous system.  It coordinates and 
integrates all the signals for the body to function properly.  Therefore, the brain requires 
protection from the rest of the body without compromising its requirement for nutrients, 
such as oxygen and glucose.  The BBB functions to protect the brain by inhibiting toxins 
in the peripheral circulation from entering the brain, while allowing for nutrients to enter 
through the barrier.  Furthermore, it mediates waste efflux from brain to blood and 
maintains a constant environment in the brain.  
The concept of the BBB originated with the studies of Paul Ehrlich in 1885 who 
observed that water-soluble dyes injected into the circulatory system stained all organs 
except for the brain and spinal cord (Hawkins and Davis, 2005).  His student, Edwin 
Goldmann, injected dyes into the cerebral spinal fluid, which stained the brain but not 
the rest of the body (Hawkins and Davis, 2005).  These observations suggested that a 
barrier must exist separating the brain and central nervous system from the peripheral 
circulation.  Studies with silver nitrate demonstrated differences in the nervous system 
compared to the periphery (Dempsey and Wislocki, 1954).  However, it was not until the 
1960s when scientists were able to confirm the existence of a barrier at the structural 
level.  Electron microscopy showed that high doses of exogenous peroxidase failed to 
penetrate the brain vascular endothelium and remained in the lumina of blood vessels 
and in a few micropinocytotic vesicles within the endothelium.  This finding led to the 
conclusion that tight junctions probably were responsible for preventing intercellular 
passage of peroxidase (Reese and Karnovsky, 1967).  Brightman and Reese (1969) 
demonstrated in separate experiments using intravascular injections of peroxidase and 
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lanthanum hydroxide that tight junctions were present, separating the vascular lumina 
from the underlying spaces.  Furthermore, they confirmed that the tight junctions (as 
described below) in the vascular endothelium have a pentalaminar configuration, which 
is distinct from gap junctions that have a seven-layer configuration (Brightman and 
Reese, 1969). 
The BBB is comprised of endothelial cells that line cerebral microvessels.  These 
endothelial cells are characterized by few pinocytic vesicles, the absence of 
fenestrations, and a high number of mitochondria (Bernacki et al., 2008).  They originate 
from permeable capillaries of the perineural vascular plexus and invade the embryonic 
neuroectoderm to form intraneural capillaries (Wolburg et al., 1994).  The ability of the 
BBB to perform its functions is due to the presence of tight junctions, which hold the 
endothelial cells close together.  The tight junction complex is composed of tight 
junction and adherens junction proteins (Figure 1).  Tight junction proteins include 
junctional adhesion molecules (JAMs), occludin, claudins, and membrane associated 
guanylate kinase-like proteins.  JAMs are single membrane-spanning proteins are 
involved in the maintenance and formation of the barrier (Abbott et al., 2006).  Occludin 
is a transmembrane protein that functions to increase electrical resistance, and can 
interact with zona occludens protein 1 (ZO-1) in the cytoplasmic side (Hawkins and 
Davis, 2005; Abbott et al., 2006).  The claudin family consists of four transmembrane 
domains, and claudin-3 and -5 are expressed in endothelial cells of the BBB.  They 
seem to be the primary building protein of the tight junctions (Bernacki et al., 2008).  
The membrane associated guanylate kinase-like proteins are accessory proteins found 
in the cytoplasm that enable protein-protein interactions.  Two of these proteins have 
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been identified at the tight junction:  zona occludens-1 (ZO-1) and zona occludens-2 
(ZO-2).  ZO-1 links occludin to the actin cytoskeleton, and ZO-2 binds to structural 
constituents of the tight junction (Hawkins and Davis, 2005).  Adherens junctions are 
also “tightening” structures between endothelial cells and are composed of cadherins.  
These cadherins bind to the cytoskeleton via α-, β-, and γ-catenins.  It is thought that 
ZO-1 and catenins interact with each other, suggesting that tight and adherens junctions 
cooperate in maintaining the BBB (Bernacki et al., 2008). 
The tight junction complex does not allow for paracellular transport of water-
soluble agents and polar drugs.  However, the endothelial cells have various transport 
systems to allow for nutrients from the peripheral circulation to enter the brain and for 
waste to efflux from brain to blood.  Gases and lipophilic molecules are capable of 
transcellular movement.  Glucose and amino acids have the transport carriers, GLUT-1 
and LAT1 and others, respectively, to cross the BBB (Abbott et al., 2006).  Some 
transport systems are energy-dependent, such as P-glycoprotein (Pgp), multidrug 
resistant protein (MRP), breast cancer resistance protein (BCRP), organic anion 
transporting polypeptides (OATP), and organic anion transporters (OAT), which efflux 
molecules from the brain into the blood and have the potential to reduce the penetration 
of drugs into the brain (Zlokovic, 2008).  Pgp localizes on the luminal membrane of 
endothelial cells.  MRPs are also found in the luminal membrane, and are able to 
transport organic anions and neutral organic drugs (Bernacki et al.,2008).  OATPs are 
expressed on both luminal and abluminal membranes of endothelial cells, and are 
involved in the elimination of xenobiotics (Tamai et al., 2000), and amphipathic organic 
solutes (Bernacki et al, 2008).  OATs, particularly OAT3, are expressed in brain 
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Figure 1.1.  The organization of the tight junction.  The tight junction is 
comprised of occludin, claudin 3/5, and JAMs, which form a tight seal between 
endothelial cells.  The tight junction proteins also interact with the membrane 
associated guanylate kinase-like proteins, such as ZO-1 and ZO-2, that are found 
in the cytoplasm of the endothelial cells.  ZO-1 and -2 link tight junction proteins to 
the actin cytoskeleton and other accessory proteins in the cytoplasm. 
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capillaries on the abluminal side, and its substrates include amphipathic organic anions, 
hydrophilic organic anions, and organic cations (Ohtsuki, 2004).  Insulin and transferrin 
are taken up by receptor-mediated transcytosis while plasma proteins are transferred by 
absorptive transcytosis if they undergo cationization (Abbott et al., 2006).  Ion 
transporters such as Na+/K+-ATPases, Na+-K+-2Cl- cotransporter, and the Na+/H+ and 
Cl-/HCO3- exchangers are also present. 
The endothelial cells that line the cerebrovasculature are supported and interact 
with other structures to form the neurovascular unit (NVU).  The NVU comprises 
astrocytes, neurons, and pericytes interacting with the smooth muscle and endothelial 
cells of the microvessel (Hawkins & Davis, 2005; Abbott et al., 2006).  Anatomically, 
astrocytes wrap around the microvessels with their endfeet making contact with the 
vessel wall (Nedergaard et al., 2003).  Furthermore, astrocytes secrete various growth 
factors such vascular endothelial growth factor (VEGF) during retinal angiogenesis, and 
continue to form and maintain the blood-retinal barrier (Uemura et al, 2008).  Astrocytes 
have a role in inducing BBB properties in vitro (Rubin et al., 1991).  It has been reported 
that with astrocyte loss there is tight junction disruption and loss of BBB integrity (Willis 
et al., 2004).  Neurons are highly metabolic, and therefore have a close relationship with 
endothelial cells.  With astrocytes as the intermediary, neurons and endothelial cells 
have bi-directional communication.    The arrangement of neurons and microvessels 
varies depending on location within the brain.  In grey matter, microvessels grow in 
hexagonal arrays whereas, in white matter, they are arranged in line with the axons (del 
Zoppo, 2010).  Neurons modulate BBB function, but it is not known if they are involved 
in BBB development (Hawkins and Davis, 2005).  Pericytes encircle the wall of the 
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microvessel, and their processes can penetrate the basement membrane and make 
contact with the endothelium (Hirschi and D’Amore, 1996).  They regulate microvessel 
diameter by constricting the vascular wall (Peppiatt et al., 2006; Bell et al., 2010).  They 
also regulate endothelial cell activity and mediate inflammation (Bernacki et al., 2008). 
Alterations in the BBB have been implicated in aging and many diseases.  
Research has focused on the role of BBB dysfunction in neurodegenerative diseases 
such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic 
lateral sclerosis (ALS).  In Alzheimer’s disease, there is upregulation of GLUT1 and 
increased glucose transport.  Furthermore, there is also a decrease in Pgp, leading to 
an increase in amyloid-β (Abbott et al., 2006).  Low activity of Pgp has been observed in 
Parkinson’s disease (Abbott et al., 2006; Zlokovic, 2008).  Leukocyte extravasation 
across the endothelium is believed to occur in multiple sclerosis, and BBB breakdown is 
thought to lead to the pathogenesis of ALS (Zlokovic, 2008).  BBB dysfunction has also 
been implicated in inflammation, hypoxia/ischemia, pain, and human immunodeficiency 
virus-1 (HIV-1) infection (Hawkins and Davis, 2005; Abbott et al., 2006; Zlokovic, 2008). 
 
The BBB in Diabetes 
 BBB dysfunction has been well established in diabetes.  Changes in glucose and 
amino acid transport, structural and molecular alterations, and permeability have been 
observed in diabetic animal models.  Studies regarding glucose transport during 
hyperglycemia have yielded mixed results.  Gjedde et al. (1981) showed that glucose 
transport decreased in diabetic rats despite the fact that cerebral blood flow did not 
change in either the diabetic or control group.  These results were supported by a study 
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by McCall et al. (1982).  However, Pelligrino et al. (1990) demonstrated that glucose 
transport increased in chronically hyperglycemic diabetic rats compared to controls.  
However, other studies have shown that hypoglycemia increases glucose transport 
across the BBB (Simpson et al., 1999). 
 Transport of amino acids into the brain is important for its function.  Many amino 
acids, such as tryptophan and tyrosine, are precursors for neurotransmitters in the brain 
and central nervous system.  It has been shown that transport of the amino acids 
tryptophan, tyrosine, and lysine does not change in diabetic rats versus control.  
Ketone-body transport in the form of β-hydroxybutyrate is lower in diabetic animals and 
is restored or increased upon insulin treatment (McCall et al., 1982).  Furthermore, 
glutamate transport at the BBB is not affected by diabetes in two rat models of diabetes 
(Hawkins, 2009).  Additionally, elevated plasma amino acids leads to a reduced flux of 
large neutral amino acids across the luminal membrane of the BBB (Mann et al., 2003). 
Structural and molecular changes of the BBB are evident in diabetes.  Capillary 
basement membrane thickening occurs, and the density of transcytotic vesicles 
increases (Tolia et al., 2005).  Additionally, there have been reports of changes in tight 
junction protein expression.  It has been reported that diabetic rats not treated with 
insulin have a reduced occludin expression compared to insulin-treated or control rats 
whereas ZO-1 remained unaltered (Chehade et al., 2002).  Hawkins et al. (2007) saw a 
similar decrease in occludin content, which together with an increase in MMP resulted in 
a permeability increase.  As diabetes progressed, there was further disruption in the 
BBB and a region-specific permeability increase (Huber et al., 2006).  Tight junction 
protein expression and permeability changes can be prevented with the administration 
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of seasmol, a natural antioxidant (VanGilder et al., 2009).  Additionally, changes in the 
transport systems at the BBB have been observed in diabetes.  Hawkins et al. (2007) 
have demonstrated decreased permeability to fluorescein, a marker for paracellular 
permeability as well as a substrate for OAT3 and MRP2, in diabetic rats.  In their study, 
decreased permeability of fluorescein was in conjunction with an increase in MRP2 
protein expression, but not OAT3 expression (Hawkins et al., 2007).  Other transport 
systems and receptors involved in brain efflux are also affected in diabetes.  It has been 
shown that low-density lipoprotein receptor related protein 1 (LRP1), a transporter at the 
BBB responsible for amyloid-β peptide (Aβ) clearance, is down-regulated in an animal 
model of diabetes, and clearance of Aβ is significantly decreased (Hong et al., 2009).  
Additionally, it has been demonstrated that the receptor for advanced glycation end 
products (RAGE) is up-regulated at the BBB leading to the deposition of Aβ in the brain 
(Liu et al., 2009).   
Changes in permeability to various substances can be dependent on the duration 
of diabetes.  Studies have demonstrated inconsistent results on albumin permeability.  
In one study, albumin permeability increased (Bouchard et al., 2002); however, in 
another study albumin permeability remained unaltered (Dai et al., 2002).  Interestingly, 
permeability of sucrose did not change in an experimental model of diabetes as the 
disease progressed (Bradbury et al., 1991).  Clinical studies using gadolinium-magnetic 
resonance imaging techniques showed a BBB permeability increase in diabetic patients 
compared to control patients (Starr et al., 2003).  Lacunar infarcts, or small 
microvascular strokes, are common in diabetes, and it has been suggested that BBB 
failure, that is, leakage of the walls of small cerebral vessels, may be a mechanism 
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(Wardlaw et al., 2003).  The mechanism of the observed permeability changes is not 
known.  Other studies at the blood-retinal barrier showed similar events, and implicated 
vascular endothelial growth factor (VEGF) as likely candidate for the observed 
permeability change (Antonetti et al., 1998).  
 
Vascular Endothelial Growth Factor (VEGF) 
The VEGF family 
  The VEGF family consists of several members, VEGF-A, -B, -C, -D, -E, -F and 
placenta growth factor (PLGF), but the most studied is VEGF-A.  They are dimeric 
glycoproteins that act through three cell surface receptor tyrosine kinases, known as the 
VEGF receptors (VEGFRs).  VEGF-A, -B, and PLGF bind to VEGFR-1 (Flt-1); VEGF-A 
and –E bind to VEGFR-2 (Flk-1); VEGF-C and –D bind to VEGFR-3; and VEGF-F binds 
to both Flk-1 and Flt-1 (Olsson et al., 2006).  Alternative splicing results in various forms 
of VEGF-A:  VEGF-A121, -A145, -A165, -A189, and –A206 (Olsson et al., 2006), with VEGF-
A165 being the most abundant human isoform (Wirostko et al., 2008) (Figure 1.2).  
VEGF-A is important for vasculogenesis (blood vessel growth from endothelial 
progenitor cells) and angiogenesis (blood vessel growth from pre-existing vessels).  If 
there is inactivation of a VEGF allele, embryonic lethality occurs at embryonic day 11-12 
in mice and tetraploid embryos, resulting in vascular defects and cardiovascular 
abnormalities (Carmeliet et al., 1996; Otrock et al., 2007; Lohela et al., 2009).  VEGF 
expression is down-regulated after embryogenesis (Breier et al., 1992), but is up-
regulated during physiological and pathological angiogenesis (Ferrera et al., 2003).  
Additionally, VEGF is important for neurogenesis, and reduced levels of VEGF leads to   
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neurodegeneration by impairing the perfusion of neural tissue (Storkebaum and 
Carmelier, 2004). 
VEGF Receptors 
The VEGF receptors are cell surface tyrosine kinase receptors.  VEGFR-1, 
henceforth called Flt-1, acts as a decoy receptor by sequestering VEGF and regulates 
the interaction between VEGF and VEGFR-2 (Flk-1) by sequestering VEGF (Wirostko 
et al., 2008).  Flt-1 is important for blood vessel development during embryogenesis, 
and plays an important role in pathological angiogenesis and wound healing by the 
interaction with Flk-1 (Cebe-Suarez et al., 2006).  Flt-1 has poor catalytic activity 
compared to Flk-1 and the downstream signaling pathways upon its activation are not 
well known.  Flk-1 is involved in permeability, angiogenesis, vasculogenesis, and 
proliferation (Holmes et al., 2007; Wirostko et al., 2008).  VEGFR-3 is important for 
wound healing, and sFlt-1 (soluble VEGFR-1) scavenges available VEGF (Wirostko et 
al., 2008).  Flk-1 and VEGFR-3 are also involved in lymphatic angiogenesis (Cebe-
Figure 1.2.  The isoforms of VEGF.  Alternative splicing of VEGF 
yields various isoforms, with VEGF165 being the most studied isoform. 
15 
 
Suarez et al., 2006).  These receptors have an extracellular domain with 
immunoglobulin-like folds, followed by a transmembrane region, a tyrosine-kinase 
domain, and kinase insert, ending with a C-terminal tail (Wirostko et al., 2008).  VEGF 
exerts its effect by binding to Flt-1 and Flk-1 receptors as well as the neuropilin 
receptors, NP-1 and NP-2.  VEGF binding leads to dimerization and subsequent 
autophosphorylation.  This action can lead to either increased permeability or 
angiogenesis (Figure 1.3).  
Flk-1 activation can lead to proliferation, migration, survival, and permeability.  
Proliferation is due to the phosphorylation of tyrosine 1175, leading to Erk 
phosphorylation via PLCγ recruitment and a PKC-dependent pathway.  Upon activation 
at tyrosine 1175, PLCγ is phosphorylated and then hydrolyzes phosphatidylinositol 
(4,5)-bisphosphate into diacyglycerol (DAG) and inositol (1,4,5)-triphosphate (IP3).  IP3 
increases intracellular calcium while DAG activates protein kinase C (PKC), which can 
then activate the Erk signaling pathway.   
Migration of endothelial cells can occur due to the phosphorylation of either 
tyrosine 1214 or 951.   Phosphorylation of tyrosine 1214 allows for the activation of the 
p38 MAPK signaling pathway and recruitment of Hsp27 for actin remodeling.  Tyrosine 
951 activation leads to phosphorylation of Src and subsequent actin reorganization.  
Migration can also occur with the phosphorylation of tyrosine 1175, with the subsequent 
activation of PI3K and formation of PIP3.  PIP3 leads to activation of Rho, which 
ultimately leads to actin reorganization and migration.  Phosphorylation of tyrosine 1175 
can also lead to migration via the recruitment of FAK, followed by focal adhesion 
turnover.  Cell survival occurs with the phosphorylation of tyrosine 1175, leading to 
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Figure 1.3.  Schematic diagram of VEGF signaling.  VEGF is able to 
bind to two classes of receptors: VEGFRs and the neuropilins.  The 
VEGFRs are Flt-1 and Flk-1, a decoy receptor and the active receptor, 
respectively.  Neuropilins enhance VEGF/Flk-1 signaling and are 
required for full activation of Flk-1.  The binding of VEGF to the 
receptors causes dimerization and autophosphorylation of specific 
tyrosine residues on the Flk-1 receptor.  Phosphorylation of these 
tyrosine residues leads to signaling pathways involved in permeability, 
migration, and proliferation.  SEMA 3A is an antagonist of VEGF, and 
exerts its effects by binding to the neuropilin receptors, thereby blocking 
VEGF from binding to this class of receptors.  SEMA 3A is also known 
as a permeability factor as well, independent of VEGF-induced 
permeability.  (Figure courtesy of Dr. Richard Egleton) 
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PIP3 formation via PI3K.  PIP3 causes phosphorylation of Akt/PKB, which inhibits the 
pro-apoptotic protein, Bad, and caspase-9 activation.   
Permeability of the endothelium occurs via activation of tyrosine 951 or 1175.  
Phosphorylation at tyrosine 951 leads to activation of Src and actin reorganization as 
seen during migration.  At tyrosine 1175, PI3K is activated, followed by PIP3 formation.  
As with cell survival, PIP3 causes phosphorylation of Akt/PKB; however, Akt will lead to 
the activation of endothelial nitric oxide synthase (eNOS).  eNOS will lead to an 
increase in nitric oxide (NO) production, which will facilitate a permeability increase in 
endothelial cells. 
Neuropilin Receptors 
The neuropilin receptors are transmembrane glycoproteins important for axonal 
guidance, angiogenesis, tumorigenesis, and are involved in the immunologic response 
(Sulpice et al., 2008).  The receptors denoted NP-1 and NP-2 act as co-receptors for 
class III semaphorins (see next section) and members of the VEGF family.  They have 
large extracellular domains and a short cytoplasmic tail that lacks enzymatic activity 
(Sulpice et al., 2008).  However, the lack of enzymatic activity remains unclear as tumor 
cells lack the Flk-1 receptor, but express neuropilin receptors (Geretti et al., 2008).  
Their extracellular domains consist of (1) a signal sequence; (2) two complement 
factors, a1 and a2; (3) two coagulation factors, b1 and b2; and a (4) c domain, which is 
homologous to A5.  The length of these domains is similar between the two receptors, 
but they have varying degrees of conservation (Kolodkin et al., 1997).  The binding site 
for VEGF is located in the b1 and b2 domains whereas SEMA 3A requires both a and b 
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domains (Geretti et al., 2008; Sulpice et al., 2008).  Furthermore, NP-1 and NP-2 bind to 
VEGF-A165 with different affinities 
NP-1 was initially identified as an antigen to the antibody, A5, which was raised 
against proteins in the optical tectum of Xenopus tadpoles (Geretti et al., 2008; Pellet-
Many et al., 2008).  NP-1 has a large extracellular domain followed by a short 
transmembrane domain and an intracellular domain.  It is expressed in neural tissues, 
particularly during development of the central nervous system, but is also present in 
non-neuronal tissues in adults particularly in the placenta, heart, tumor-derived cells, 
and endothelial cells (Staton et al., 2007).  In the vasculature, it is primarily expressed 
on the arterial end of endothelial cells (Staton et al., 2007; Sulpice et al., 2007).  NP-1 
can undergo post-translational modification by the addition of glycosaminoglycan in the 
linker region between b2 and c domains (Pellet-Many et al., 2008).  In endothelial cells, 
this modification of NP-1 enhances the VEGF/Flk-1 signaling, perhaps by stabilizing the 
Flk-1 receptor and preventing its internalization and degradation (Shintani et al., 2006).  
Furthermore, VEGF interaction with NP-1 is required for full activation of the Flk-1 
receptor (Sulpice et al., 2008).  Mutations in NP-1 results in vascular defects, including 
impaired neural vascularization, defects in the great vessels, heart outflow tracts, and in 
the vasculature of yolk sacs (Kawasaki et al., 1999).  In addition to VEGF-A165, NP-1 
can bind to VEGF-B, -E, and PLGF (Koch et al., 2011). 
NP-2 was originally identified as an alternative receptor to the semaphorins 
involved in axonal guidance (Kolodkin et al., 1997; Staton et al., 2007).  It is expressed 
in endothelial cells, primarily at the venous side as well as in lymphatic endothelial cells 
(Staton et al., 2007).   The receptor binds to VEGF-A165, VEGF-A145, VEGF-C, and 
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VEGF-D (Soker et al., 1998; Koch et al., 2011; Staton et al., 2007).  NP-2 co-localizes 
and directly interacts with VEGFR-3 in lympathic vessels (Karpanen et al., 2006; Staton 
et al., 2007).  Defects in NP-2 result in abnormalities in lymphatic vessels and 
capilliaries (Staton et al., 2007).  As with NP-1, NP-2 enhances the affinity of VEGF to 
Flk-1 and increases its phosphorylation (Shraga-Heled et al., 2006; Sulpice et al., 
2008). 
The neuropilin receptors are involved in both physiological and pathological 
angiogenesis.  Neuropilins are believed to be involved in angiogenesis during the 
menstrual cycle because both NP-1 and NP-2 are expressed in endothelial cells in 
response to estrogen and progesterone (Staton et al., 2007).  Additionally, it has been 
shown that NP-1 expression is up-regulated during wound healing (Staton et al., 2007; 
Matthies et al., 2002).  However, it has been documented that mice which express NP-1 
without its cytoplasmic domain undergo normal vasculogenesis and angiogenesis 
(Fantin et al., 2011).  On the other hand, the role of neuropilins has been well 
documented in pathological angiogenesis.  Overexpression of NP-1 resulted in 
increased tumor vascular density (Miao et al., 2000; Bagri et al., 2009).  NP-1 is 
expressed in many human cancer cell lines (Bagri et al., 2009) with varying levels of 
expression (Staton et al., 2007).  In pancreatic adenocarcinoma, NP-1 and NP-2 
exhibited higher mRNA expression levels than Flt-1 and Flk-1 (Fukahi et al., 2004). 
Semaphorin 3A (SEMA 3A) 
 The semaphorin family is a group of proteins that is subdivided by class specific 
domains and domain organization.  These proteins are subdivied into eight classes, 1-7 
and V.  Classes 2, 3, and V semaphorins are secreted, and all other classes of 
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semaphorins are membrane bound (Tran et al., 2007).  Semaphorins are best known in 
participating in both short and long range axonal cues.  They mostly act as a repellent to 
maintain nerve bundling, process extension, and sculpting arborization patterns (Tran et 
al., 2007).  Semaphorins execute their functions via the plexin receptors, which can be 
divided into four classes, A-D.   
 In addition to axonal cues, semaphorins, particularly class 3 semaphorins, 
regulate vascular development, tumor progression, metastasis, the immune response, 
and platelet function (Bielenberg and Klagsbrun, 2007).   SEMA 3A also modulates 
blood vessel formation through the inhibition of integrin activity (Soker et al., 1998; 
Acevedo et al., 2008).  SEMA 3A interacts indirectly with the plexin A1 receptor, but it 
requires NP-1 and NP-2 as a co-receptor to assemble the ligand-receptor complex and 
cause activation (Tran et al., 2007).  Little information is known on the role of plexins in 
the receptor complex (Casazza et al., 2011).  It has been shown that SEMA 3A disrupts 
VEGF-mediated migration of endothelial cells (Miao et al., 1999; Acevedo et al., 2008).  
Additionally, SEMA 3A is anti-angiogenic within the tumor vasculature (Maione et al., 
2009) and reduces the number of pericyte-coated vessels (Casazza et al., 2011).  
SEMA 3A deletion leads to excess endothelial cells in the capillaries of the kidney, and 
its overexpression results in the down-regulation of Flk-1 (Reidy et al., 2009).  Because 
VEGF and SEMA 3A share a common receptor, it is likely that SEMA 3A regulates 
VEGF function.  Indeed Acevedo et al. (2008) showed that SEMA 3A suppresses 
VEGF-mediated angiogenesis but also acts as a permeability factor.  SEMA 3A 
antagonizes VEGF interaction with the neuropilin receptor and prevents the dimerization 
and angiogenesis.   
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The Streptozotocin (STZ) Model of Diabetes 
 Streptozotocin (STZ, 2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyranose) is 
a nitrosourea analogue synthesized by Streptomycetes achromogenes and has been 
used clinically as an antimicrobial and chemotherapeutic agent (Figure 1.4).  In 
research settings, it has also been widely used to induce insulin-dependent, or T1D.  
Alloxan, another drug used to induce T1D, has been used in research settings, but 
there are some differences between alloxan and STZ:  (1) The selectivity of STZ on β-
cells is greater than alloxan; (2) the dosage range is broader in alloxan administration 
than with STZ; (3) a subdiabetic dose of STZ, followed by a second identical dose leads 
to increased diabetogenic activity, which is not seen with alloxan; and (4) the 
diabetogenic activity of STZ is not influenced by changes in nutritional state, unlike the 
activity of alloxan in which changes in sensitivity are induced by fasting or feeding 
(Junod et al., 1969).  Alloxan can also affect the liver by decreasing non-protein and 
protein-bound sulhydryl groups, which could lead to inactivation of enzymes (Szkudelski 
et al., 1998).  Additionally in comparison with alloxan, STZ produces permanent 
diabetes, which is ideal for T1D studies, and its use is more reproducible and better for 
the induction of diabetes that is appropriate for endocrine and metabolic studies 
(Karunanayake et al., 1974). 
 Diabetes results from beta cell toxicity and subsequent beta cell death through 
necrosis (Lenzen, 2008).  These events occur because STZ is transported into the beta 
cells of the pancreas via the GLUT2 transporter and causes methylation of nucleic acids 
and proteins (Konstantinov and Berger, 2008).  The cell attempts to overcome this 
damage by the activation of poly(ADP-ribose) polymerase (PARP), which then leads to 
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depletion of pyridine nucleotides, nicotine adenine dinucleotide (NAD) and its reduced 
form, NADH, and subsequently, ATP (Lenzen, 2008) (Figure 1.5).  Additionally, there is 
speculation that STZ induces diabetes through oxidative stress.  STZ-induced diabetes 
can also lead to an increase in nitric oxide (NO) production (Figure 1.5).  NO acts as a 
modulator of oxidative stress, and is also a free radical in the form of NO·.  Studies have 
shown that pancreatic islets have higher nitrate/nitrite levels in STZ-treated animals 
versus control, and that NO had deleterious effects on the enzymes that are protective 
in oxidative stress (Gonzalez et al., 2000).   It has also been reported that NO-synthase 
(NOS) inhibitors, such as NG-nitro-L-arginine-methyl ester (L-NAME), can lead to 
attenuation of STZ-induced hyperglycemia in mice (Kolb et al., 1991).  Haluzik and 
Nedvidkova (2000) demonstrated that two NOS inhibitors, L-NAME and methylene blue, 
were able to partially suppress the development of STZ-induced diabetes. 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  Chemical structure of streptozotocin. 
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Streptozotocin can be injected intravenously in adult rats as well as 
intraperitoneally at concentrations between 40 to 60 mg/kg or higher (Szkudelski, 2001).  
There is a triphasic glucose response upon streptozotocin administration (Lenzen, 
2008).  During the first phase, hyperglycemia with a decrease in blood insulin is evident 
within two hours of STZ administration.  Beta cells exhibit morphological changes such 
as intracellular vacuolization, dilation of the rough ER, decreased area of the Golgi, 
reduced secretory granules and insulin content, and swollen mitochondria (Lenzen, 
2008).  Hypoglycemia, along with high levels of blood insulin, occurs after six hours.  
The last phase is hyperglycemia and a decrease in blood insulin levels (Szkudelski, 
2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.  Mechanism of STZ-induced diabetes.  
STZ is able to enter the pancreatic beta-cell via the 
GLUT2 transporter.  It primarily induces DNA 
alkylation, but can also affect proteins.  This leads to 
activation of PARP and subsequent reduction of 
NAD
+
, NADH, and ATP.  Additionally, STZ is also able 
to lead to an increase in nitric oxide production and 
development of free radicals, which can result in DNA 
damage as well. 
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STZ is primarily administered via single injection; however it can be administered 
with multiple injections depending on concentration.  The half-life of STZ is about 15 
minutes.  Interestingly, beta cell necrosis begins within 24 hours after injection (Like and 
Rossini, 1976).  Using radiolabelling studies, Karunanayake et al. (1974) demonstrated 
that after 15 minutes there was intense accumulation of STZ in the kidney and STZ liver 
uptake reached its maximum at 30 minutes after injection.  Thus, it seems likely that 
only a small amount of STZ is required to reach the pancreas to induce its toxic effects. 
 
Hypothesis and Specific Aims 
In diabetes, BBB permeability increases.  However, the mechanism of this 
permeability change is not known.  The goal of this project is to determine the 
mechanism of the permeability increase using the streptozotocin (STZ) model of 
diabetes, which is a well characterized type I model.  I hypothesized that the increase in 
permeability at the BBB is due to VEGF and its interaction with the Flk-1 receptor, and 
subsequent activation of a signaling pathway involved in permeability.  I also 
hypothesized that these BBB changes can be attenuated by administration of a possible 
therapeutic agent, minocycline.   
Specific Aim 1:  To investigate if minocycline is able to attenuate the observed 
BBB changes in an STZ model of diabetes. 
Specific Aim 2:  To investigate the role of the VEGF signaling system as a 
mechanism for the observed BBB changes.  
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Chapter 2:  Minocycline Decreases Blood-Brain Barrier Permeability Yet 
Increases Vascular Endothelial Growth Factor in the Streptozotocin Model of 
Diabetes 
 
Abstract 
Diabetes is associated with increased permeability and a decrease in tight 
junction protein expression at the blood-brain barrier (BBB).  There are no clinical 
treatments to attenuate the BBB changes in diabetes, though several strategies have 
been used in animal models.  Minocycline (MIN), a tetracycline antibiotic, has anti-
inflammatory properties and is able to cross the BBB.  Minocycline attenuates BBB 
disruption via a number of proposed mechanisms including inhibition of microglia 
activation, antioxidant activity, and matrix metalloproteinase inhibition.  Minocycline may 
protect against the previously reported changes in diabetic BBB function.  This study 
tests whether minocycline can attenuate the BBB changes observed in the 
streptozotocin (STZ) model of diabetes.  Minocycline decreased permeability and 
increased expression of tight junction proteins, especially claudin-5.  Furthermore, 
minocycline increased protein expression of vascular endothelial growth factor (VEGF), 
a potent angiogenic and permeability factor, in cerebral microvessels.  Additionally, 
minocycline treatment increased in protein expression of Flt-1.  These results indicate 
that minocycline may be a potential therapeutic agent to decrease the permeability 
changes observed at the BBB in diabetes.   
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Introduction 
The blood-brain barrier (BBB), a semi-permeable vascular interface, is located at 
the level of brain microvascular endothelial cells.  The BBB regulates the CNS 
extracellular environment by restricting entry from blood into brain.  It allows nutrients 
from the periphery to pass and mediates waste efflux from brain to blood.  However, in 
many pathological conditions, the barrier and its functions are compromised, which can 
lead to edema and leukocyte transmigration across the barrier.  These events can 
activate microglia, the immune cells of the CNS, which generate immunomodulatory 
molecules (Yenari et al., 2006).      
 In neurodegenerative diseases, such as ischemia, Parkinson’s disease, spinal 
injury, multiple sclerosis, and others, treatment with minocycline, a tetracycline antibiotic 
and anti-inflammatory agent, results in neuroprotection.  Minocycline is of particular 
interest in these diseases because it crosses the BBB and reaches therapeutic 
concentrations in the brain (Zemke and Majid, 2004).   Minocycline inhibits microglial 
activation, and functions to decrease apoptosis and the production of reactive oxygen 
species (Plane et al., 2010).  Minocycline exerts its anti-inflammatory effects by 
decreasing proliferation and activation of microglia, which leads to decreased release of 
cytokines, matrix metalloproteinases, and other inflammatory mediators (Kim and Suh, 
2009).  It also inhibits transmigration of T lymphocytes (Kim and Suh, 2009).  
Minocycline also has both caspase-dependent and –independent anti-apoptotic effects.  
Last, minocycline is involved in signaling pathways, particularly in the inhibition of p38 
MAPK activation in microglia (Hau et al., 2005).  Minocycline is protective in a rat model 
of ischemia (Yrjanheikki et al., 1999; Zemke and Majid, 2004).  Wasserman and 
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Schlichter (2007) demonstrated that administration of minocycline protected the BBB 
and reduced edema after intracerebral hemorrhage.   In the retina, minocycline 
stimulates chemotaxis and decreases proliferation of retinal pigment epithelial cells, and 
also promotes the expression of platelet derived growth factor (PDGF), hepatocyte 
growth factor (HGF), vascular endothelial growth factor (VEGF), and MMP-9 (Hollborn 
et al., 2010). 
Diabetes is a risk factor for stroke and other cerebrovascular diseases.  Clinical 
studies using magnetic resonance imaging-gadolinium techniques have shown that the 
BBB exhibits increased permeability (Starr et al., 2003).  This permeability increase has 
also been shown in the STZ model of diabetes, in conjunction with decreased tight 
junction protein expression of occludin and zona occludins-1 (ZO-1) as well as an 
increase in MMP-2, which may also contribute to BBB dysfunction (Hawkins et al., 
2007).  The increased BBB permeability can be attenuated by therapeutic intervention 
through statins (Mooradian et al., 2005) and sesamol, a natural antioxidant (VanGilder 
et al., 2009). 
The mechanism of this BBB permeability change, however, has not been 
elucidated.  Other studies using the STZ model have shown similar changes in the 
blood-retinal barrier and demonstrated that VEGF plays a role in the permeability 
changes (Antonetti et al., 1998).  VEGF functions as a potent pro-angiogenic and 
permeability factor, and its signaling system is a likely candidate for the permeability 
changes occurring at the BBB.  VEGF signaling occurs via its receptors, Flt-1 and Flk-1, 
as well as its co-receptors, neuropilin-1 and -2 (NP-1 and NP-2) and endogenous 
antagonist, semaphorin 3A (SEMA 3A).  NP-1 and NP-2 enhances VEGF binding to Flt-
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1 and Flk-1 receptors.  SEMA 3A binds to the neuropilin receptors, thus inhibiting the 
ability of VEGF to interact with these co-receptors.  Interestingly, SEMA 3A suppresses 
angiogenesis and also acts as a permeability factor through the neuropilins (Acevedo et 
al., 2008).  In this study, we investigate whether minocycline can attenuate the 
functional and molecular changes at the BBB in the STZ model of diabetes.  
Furthermore, we examined the VEGF signaling system in the diabetic brain 
microvasculature, and whether minocycline has any effect on its expression.  
  
Methods 
Animal Care 
Animal procedures were performed in strict accordance with the Institutional 
Animal Care and Use Committee, Marshall University.   Male Sprague-Dawley rats 
(Hilltop Laboratories, Scottdale, PA) were injected with either 65 mg/kg STZ (Sigma, St. 
Louis, MO) or 0.9% sterile saline.  Seven days after STZ injection, animals were 
injected with 22 mg/kg minocycline or 0.9% sterile saline twice daily for the reminder of 
the study.  The following conditions were maintained:  12h-12h dark-light cycle, with 
ambient temperature of 22 ± 2º C, food and water given ad libitum.  Animals were 
euthanized 14 days after STZ injection via intramuscular injection of a 1 mL/kg cocktail 
containing ketamine (71.5 mg/mL) and xylazine (5.7 mg/mL).  Blood samples were 
collected from the descending aorta, and tested for glucose, ketones, and lipids with an 
analyzer (CardioChek PA, Polymer Technology Systems, Indianapolis, IN).     
In situ perfusion 
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In situ perfusion studies were performed in the laboratory of Dr. Richard Egleton 
at the University of Arizona.  Rats were anaesthetized with ketamine and heparinized by 
intra-peritoneal injection (10,000 U/kg).  The common carotid arteries were exposed 
after a midline incision was made at the neck.  Both arteries were cannulated, and the 
jugular veins were sectioned.  The brain was then perfused with an oxygenated 
mammalian Ringer solution [in mM: 117 NaCl, 4.7 KCl, 0.8 MgSO4, 24.8 NaHCO3, 1.2 
KH2PO4, 2.5 CaCl2, and 10 D-glucose, with 39 g/l dextran (mol wt 70,000) and 10 g/l 
BSA, pH 7.4] with Evans blue at 37°C.  When the desired perfusion pressure and rate of  
∼100 mmHg and 3.1 ml/min was reached, [14C]sucrose (10 μCi/20 ml Ringer) was 
infused via a slow-drive syringe pump (0.5 ml·min−1·hemisphere−1; model 22, Harvard 
Apparatus, South Natick, MA).  After a 20 minute perfusion (n = 4-6 per treatment), the 
rat was decapitated and the brain was removed.  Samples of the radioactive perfusate 
were collected from each carotid cannula as a reference. Next, the choroid plexuses 
and meninges were removed, and the cerebral hemispheres were sectioned and 
homogenized. Brain tissue and 100 μl samples of perfusate were incubated for two 
days in 1 ml of tissue solubizer (TS-2, Research Products, Mount Pleasant, IL) in 
preparation for liquid scintillation counting.  Finally, 100 μl of 30% acetic acid and 4 ml of 
Budget-Solve Liquid Scintillation Cocktail (Research Products) were added, and the 
samples were measured for radioactivity (model LS 5000 TD Counter; Beckman 
Instruments, Fullerton, CA). Results are reported as a distribution volume (Rbr) of 
radioactivity in the brain to that in the perfusate:  
𝑅𝑏𝑟 = 𝑑𝑝𝑚.𝑔−1 𝑏𝑟𝑎𝑖𝑛 𝑡𝑖𝑠𝑠𝑢𝑒𝑑𝑝𝑚.𝑚𝑙−1𝑝𝑒𝑟𝑓𝑢𝑠𝑎𝑡𝑒  
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Cerebral Microvessel Isolation 
Cerebral microvessel isolation was performed as described by Hawkins et al., 2007.  
After anesthetization, brain was removed and placed in a petri dish with a buffer solution 
A (for 1 L:  6.02 g NaCl, 0.35 g KCl, 0.368 g CaCl2, 0.163 g KH2PO4, 0.296g MgSO4, 
3.57 g HEPES, pH 7.4, 4oC).  Under a dissecting microscope, meninges and choroid 
plexus were removed.  The cortex was dissected from brainstem and cerebellum.  The 
whole brain was minced and homogenized in 5 mL buffer solution B  (for 1L:  6.02 g 
NaCL, 0.35 g KCl, 0.368 g CaCl2, 0.163 g KH2PO4, 0.296g MgSO4, 3.57 g HEPES, 2.1 
g NaHCO3, 0.11 g sodium pyruvate, 10 g dextran (~64 kDa), 1.8 g glucose, pH 7.4, 
4oC).  The homogenate was poured into a 50 mL tube through a 100 µm cell strainer.  
The homogenate was transferred to a 30 mL centrifuge tube (Beckman Ultra-Clear), 20 
mL of 26% dextran was added and spun for 10 minutes at 5800 g.  After spinning, the 
thick white layer at the top of tube was removed.  A pale white streaky pellet on the side 
of the tube remained, resuspended in 10 mL buffer solution B, and passed through a 70 
µm cell strainer.  The suspension was transferred to a 30 mL centrifuge tube and spun 
at 500 g for 10 minutes.  The supernatant was removed, and the final microvessel pellet 
was resuspended in either tissue extraction buffer (ThermoScientific, Rockford, IL) for 
protein extraction or TriReagent (Sigma, St. Louis, MO) for RNA isolation.  Protein was 
analyzed using bicinchoninic acid (BCA) protein assay kit (ThermoScientific, Rockford, 
IL).   
Western Blot Analysis of Immunoreactive Protein 
Protein samples (20 µg/well) were separated via SDS gel electrophoresis using 
4-12% Bis-Tris gel (Criterion, Bio-Rad, Hercules, CA) followed by transfer to 
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nitrocellulose paper.  Occludin, claudin-5, and ZO-1 antibodies were purchased from 
Invitrogen, Life Technologies (Grand Island, NY).  Antibodies directed against VEGF, 
VEGF receptors (Flt-1, Flk-1, NP-1, and NP-2), and SEMA 3A were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA).  Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) antibodies (EMD Millipore, Billerica, MA) were used to 
normalize protein loading.  Protein bound to each antibody was detected by horseradish 
peroxidase conjugated secondary antibody (GE Healthcare Bio-Sciences, Piscataway, 
NJ), and detected by the enhanced chemiluminescence system (GE Healthcare Bio-
Sciences, Piscataway, NJ). 
Data Analysis 
The data are reported as the mean and standard error of the mean.  Statistical analysis 
for all studies was via ANOVA followed by Student-Newman-Keuls analysis. 
 
Results 
Minocycline did not prevent STZ-induced changes in blood chemistry 
Table 2.1 lists the selected blood chemistries of the animals in this study.  There 
was a significant increase in blood glucose levels in STZ-treated animals compared to 
control animals, which was not affected by minocycline treatment.  Both STZ groups 
had high blood triglyceride levels, but animals treated with both STZ and minocycline 
had a statistically significant increase in triglycerides compared to control.  Figure 2.1 
shows that STZ significantly reduced weight gain in the animals; however, this was not 
modulated by minocycline.  Additionally, there was no change in brain weights in any of 
the treatment groups (Figure 2.2).   
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Minocycline reversed STZ-induced increase in BBB permeability to sucrose 
In situ perfusion studies (Figure 2.3) showed that STZ-treated animals had a 
significant increase in BBB permeability to sucrose compared to control animals.  
Treatment with minocycline lead to a significant decrease in BBB permeability to 
sucrose in both control and STZ-treated animals (p<0.05, two way ANOVA, followed by 
Newman-Keuls; n=6 per group). 
Minocycline increased claudin-5 expression independently of STZ treatment 
Western analysis showed that neither STZ nor minocycline treatment affected 
ZO-1 (Figure 2.4) or occludin (Figure 2.5).  Although STZ did not have an effect on 
claudin-5 protein expression, treatment with minocycline resulted in a significant 
increase in claudin-5 in both control and STZ-treated animals (Figure 2.6). 
Minocycline increased protein expression of VEGF and Flt-1 
Western analysis showed that minocycline significantly increased VEGF protein 
levels in in STZ-treated animals with minocycline compared to STZ-animals treated with 
saline (Figure 2.7).    There was also a significant increase in the expression of Flt-1 in 
the control animals treated with minocycline compared to the saline-treated controls.  A 
similar trend was seen in the STZ-treated animals, though this did not reach 
significance (Figure 2.8).  Minocycline did not alter Flk-1 expression in diabetic rats 
(Figure 2.9).  Additionally, minocycline treatment had no significant effect on NP-1 
(Figure 2.10) and NP-2 (Figure 2.11) protein levels in diabetic animals.  The levels of 
SEMA 3A protein expression were not significantly decreased with minocycline 
treatment in either control or STZ-treated rats (Figure 2.12).  Interestingly, there was a  
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 Control +  
Saline 
Control + 
Minocycline 
STZ + 
Saline 
STZ +  
Minocycline 
Glucose  
(mg/dl) 
212 
(12.4) 
219 
(13.5) 
453 
(35)** 
427 
(37)** 
Ketones  
(mg/dl) 
6.93 
(0.80) 
6.99 
(1.44) 
13.07 
(2.69) 
13.31 
(2.20) 
Triglycerides 
(mg/dl) 
58.5 
(8.5) 
53.0 
(3.0) 
98.3 
(21.9) 
137 
(23.4)** 
 
Table 2.1.  Blood chemistries of control and diabetic animals treated with 
minocycline.  STZ treatment significantly increased blood glucose (**p<0.05, two-way 
ANOVA followed by Student-Newman-Keuls).  Minocycline had no effect on diabetes 
since it did not prevent the STZ-induced increase in blood glucose.  Ketones and 
triglycerides were elevated in STZ groups. (n=8 for Control + Saline; n=9 for Control + 
Minocycline; n=10 for STZ + Saline; n=9 for STZ + Minocycline) 
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Figure 2.1.  Minocycline did not prevent weight loss in STZ-treated animals.  STZ 
treatment significantly reduced body weight in the animals (p<0.01 compared to control, 
two-way ANOVA followed by Student-Newman-Keuls, n=10-14 per group).  Treatment 
with minocycline had no effect on body weight. 
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Figure 2.2.  No effect of STZ or minocycline on brain weight.  Treatment with STZ 
or minocycline did not affect whole brain weights in the animals.  (n=5 for CON +SAL 
and STZ+ MIN; n=4 for CON+ MIN and STZ +SAL). 
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Figure 2.3.  Minocycline reversed STZ-induced increase in BBB permeability.  STZ 
significantly increased BBB permeability to sucrose.  Treatment with minocycline 
significantly reduced permeability of the BBB to sucrose in both control and STZ-treated 
animals (p<0.5, two-way ANOVA followed by Newman-Keuls,  n=6 per group).  Data for 
this figure were gathered at the University of Arizona by Dr. Egleton under his radiation 
license for that institution. 
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Figure 2.4.  No effect of STZ or minocycline on ZO-1.  Neither STZ nor 
minocycline had an effect on ZO-1 protein levels.  The positive (+) sign 
indicates treatment with STZ or minocycline, and the negative (-) indicates 
no STZ or minocycline treatment.  (n=5 for CON +SAL and STZ+ MIN; n=4 
for CON+ MIN and STZ +SAL). 
 
 
ZO-1 225 kDa 
 
GAPDH  37 kDa 
STZ           -             -                   +                +          
MIN           -             +                   -                + 
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Figure 2.5.  No effect of STZ or minocycline on occludin.  No change was 
observed in occludin in any treatment. The positive (+) sign indicates treatment 
with STZ or minocycline, and the negative (-) indicates no STZ or minocycline 
treatment.  (n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and STZ 
+SAL). 
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Figure 2.6.  Minocycline treatment increased claudin-5.  There was a 
significant increase in claudin-5 protein levels in both control and STZ groups 
treated with minocycline compared to their corresponding controls (*p<0.05, 
two-way ANOVA followed by Student-Newman Keuls).  The positive (+) sign 
indicates treatment with STZ or minocycline, and the negative (-) indicates no 
STZ or minocycline treatment.  (n=5 for CON +SAL and STZ+ MIN; n=4 for 
CON+ MIN and STZ +SAL). 
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shift in the ratio of VEGF to SEMA 3A, indicating that in the minocycline-treated rats 
there should be an increase in VEGF signaling (Figure 2.13). 
Discussion 
 The goal of this study was to determine whether minocycline could attenuate the 
previously reported changes in BBB changes permeability to sucrose in the STZ model 
of diabetes.  Additionally, we investigated the effects of minocycline on VEGF and its 
receptors at the BBB.  To our knowledge, this is the first study to show that minocycline 
is able to decrease BBB permeability to sucrose in a rat model of diabetes and increase 
protein expression of tight junction proteins.  Treatment with minocycline alters the 
protein expression of VEGF and some components of its signaling pathway, implicating 
this signaling system in the response to minocycline treatment. 
 BBB integrity is compromised in diabetes.  Clinical studies demonstrated that 
there is an increase in permeability to gadolinium-DTPA at the BBB in diabetic patients 
(Starr et al., 2003).  This finding has been supported by others using animal models.  In 
the STZ model of diabetes, an increase of various markers for paracellular permeability 
have been reported including [14C] sucrose (Huber et al., 2006; Hawkins et al., 2007) 
and dextrans of varying molecular weights (Mooradian et al., 2005).  This increase in 
BBB paracellular permeability has been linked to decreased tight junction protein 
expression, in particular occludin (Hawkins et al., 2007).  In our study we also report 
that STZ-induced diabetic animals exhibited a significant increase in permeability to 
sucrose compared to control animals.  This result correlates well with the previous 
studies by our group and others (Huber et al., 2006; Hawkins et al., 2007).  In the STZ 
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animals that were treated with minocycline, the permeability to sucrose was significantly 
reduced compared to the saline-treated STZ animals (Figure 2.3).  BBB permeability in 
minocycline-treated diabetic animals was not different from control (Figure 2.3).  This 
result complements other studies that used minocycline to inhibit BBB permeability 
changes (Nagal et al., 2008; Wasserman and Schlichter, 2007).  Interestingly however, 
the permeability of the control animals to sucrose was also reduced, indicating that 
minocycline effect was not necessarily related to an inhibition of something specific to 
the STZ model.  Further, minocycline did not have a significant effect on the diabetic 
status of the animals (Table 1). 
 Changes in sucrose permeability are often linked with changes in tight junction 
protein expression.  Western analysis showed no change in either ZO-1 or occludin 
protein expression in control and diabetic animals, though the occludin was mildly 
decreased.  This result is different from our previous studies, in which we showed both 
ZO-1 and occludin decrease at the same time point (Hawkins et al., 2007).  Protein 
expression of claudin-5 did not change in the diabetic animals.  However, treatment with 
minocycline significantly increased protein expression of claudin-5 in both control and 
STZ-treated animals (Figure 2.6).  It has been suggested that claudins act as a primary 
seal for the tight junctions while occludin is present as a support structure (Hawkins and 
Davis, 2005).  Therefore, the “tighter” junction induced by minocycline may be via an 
increase in claudin-5.  To our knowledge this effect of minocycline has not been 
reported previously. Most studies only give a small number of doses, and the animals in 
this study were given minocycline twice a day for seven days.  Previous studies have 
shown that if the levels of claudin-5 are increased, then there will be a decrease in the  
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Figure 2.7.  Minocycline stimulated VEGF expression in STZ-treated 
animals.  Western analysis showed there was a significant difference 
between treatment groups (saline vs. minocycline, p<0.05, two-way ANOVA 
followed by Student-Newman-Keuls).  There was a significant increase in 
VEGF protein levels in STZ-induced diabetic animals treated with minocycline 
(*p<0.05, two-way ANOVA followed by Student-Newman-Keuls).  A similar 
trend was observed in control animals treated with minocycline.  The positive 
(+) sign indicates treatment with STZ or minocycline, and the negative (-) 
indicates no STZ or minocycline treatment.  (n=5 for CON +SAL and STZ+ 
MIN; n=4 for CON+ MIN and STZ +SAL). 
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Figure 2.8.  Minocycline increased Flt-1 expression in control animals.  
Western analysis showed that there was a significant difference between treatment 
groups (saline vs. minocycline, p<0.05, two-way ANOVA followed by Student-
Newman-Keuls).  There was a significant increase in Flt-1 protein expression in 
control animals treated with minocycline (* p<0.05, two-way ANOVA followed by 
Student-Newman-Keuls).  No change was observed in STZ-treated animals upon 
minocycline treatment.   The positive (+) sign indicates treatment with STZ or 
minocycline, and the negative (-) indicates no STZ or minocycline treatment.  (n=5 
for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and STZ +SAL). 
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Figure 2.9.  Minocycline did not have an effect on Flk-1.  Treatment with STZ or 
minocycline did not have an effect on Flk-1 protein expression (two-way ANOVA 
followed by Student-Newman Keuls).   The positive (+) sign indicates treatment 
with STZ or minocycline, and the negative (-) indicates no STZ or minocycline 
treatment. (n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and STZ +SAL). 
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Figure 2.10.  Minocycline did not affect NP-1 expression.  No significant changes 
were observed in NP-1 protein levels with STZ or minocycline treatment (two-way 
ANOVA followed by Student-Newman-Keuls).  The positive (+) sign indicates 
treatment with STZ or minocycline, and the negative (-) indicates no STZ or 
minocycline treatment.  (n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and 
STZ +SAL). 
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Figure 2.11.  No effect of minocycline on NP-2 expression.  No significant changes 
were observed in NP-2 protein levels with either STZ or minocycline treatment (two 
way ANOVA followed by Student-Newman-Keuls).  The positive (+) sign indicates 
treatment with STZ or minocycline, and the negative (-) indicates no STZ or 
minocycline treatment. (n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and 
STZ +SAL). 
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Figure 2.12.  Minocycline did not affect SEMA 3A.  Western analysis 
showed that there was no significant change in SEMA 3A protein levels with 
either STZ or minocycline treatment (two-way ANOVA followed by Student-
Newman-Keuls).  The positive (+) sign indicates treatment with STZ or 
minocycline, and the negative (-) indicates no STZ or minocycline treatment. 
(n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN and STZ +SAL). 
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Figure 2.13.  Minocycline increased the VEGF:SEMA 3A ratio.  
Western analysis showed that there was no statistically significant change 
in VEGF:SEMA 3A ratio.  Although, there appears to be a trend in an 
increase of VEGF:SEMA 3A with minocycline in both control and STZ-
treated animals.  (n=5 for CON +SAL and STZ+ MIN; n=4 for CON+ MIN 
and STZ +SAL). 
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permeability of tight junctions (Feliniski et al., 2008; Kashiwamura et al., 2011).  Thus 
the decrease in permeability seen in this study is consistent with an increased claudin-5 
expression.  Claudin-5 is known to be regulated via a number of different mechanisms.  
The tight junctions are highly dynamic structures with a constant recycling of barrier 
proteins from the junctional domain to either storage or lysosomal components (Utech 
et al., 2010; Stamatovic et al., 2011; Dukes et al., 2012).  Claudin-5 has been reported 
to be associated with caveolin-1, and its removal from the junctional complex to a 
caveolin-1-rich microdomain is associated with an opening of tight junctions (Nag et al., 
2007; Stamatovic et al., 2011).  Multiple post-translational modifications, such as 
phosphorylation and ubiquitination, of claudin-5 are associated with its recycling.  
Ubiquitination of claudin-5 appears to trigger the ubiquitin-proteasome system, leading 
to degradation, partially via a lysosomal-mediated manner (Mandel et al., 2012).  
Inhibition of this ubiquitination leads to an increase in the levels of claudin-5.  Therefore, 
it is possible that minocycline is inhibiting the recycling of claudin-5 from the membrane 
and/or its ubiquitination in both the control and STZ-treated animals.  The half-life of 
claudin-5 has been reported to be 70-90 minutes (Mandel et al., 2012).  In minocycline-
treated control and STZ-treated animals, the inhibition of claudin-5 
recycling/degradation could lead to a gradual increase in the levels of claudin-5 and a 
decrease in BBB permeability.   
The role of minocycline in regulating this BBB permeability/claudin-5 is potentially 
via a combination of mechanisms.  Minocycline is also known to inhibit MMPs, which 
have been reported to degrade several tight junction proteins including claudin-5.  In a 
recent study, doxycycline (a related tetracycline) prevented claudin-5 loss during a 
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short-term treatment strategy following MCAO, and the mechanism was proposed to be 
via a reduction in MMP activity (Wang et al., 2012).  In our model, we were looking at a 
long term treatment with minocycline (7 days), and observed an increase in control 
levels of claudin-5.  A previous study reported an increase in MMP activity in our STZ-
treated animals (Hawkins et al., 2007).  The control animals also had a small, yet 
measureable, baseline activity of MMP activity (Hawkins et al., 2007).  Therefore, it is 
possible that the MMP is involved in the basal turnover of claudin-5, and the inhibition of 
this may contribute to the accumulation of claudin-5. 
 Another mechanism in which minocycline could promote claudin-5 is via 
inhibition of PKC.  PKC activation has been shown in several cell types to alter the 
distribution of claudins (Sjo et al., 2010).  Hence, it is possible that part of the recycling 
mentioned earlier is PKC-dependent.  In fact, PKC-α has been shown to play an 
important role in caveolin-based endocytosis (Sharma et al., 2004).  As a known 
inhibitor of PKC-α, minocycline could inhibit claudin-5 recycling via this mechanism 
(Nikodemova et al., 2007), thus promoting a buildup of claudin-5 and reduced sucrose 
permeability. 
 VEGF has also been linked to not only BBB function, but also claudin-5 
regulation (Argaw et al., 2009).  Furthermore, VEGF has been linked to the tight junction 
dys-regulation in diabetes as well as diabetic-induced endothelial dysfunction 
(Murakami et al., 2012).  VEGF is involved in angiogenesis and increased permeability, 
and is a likely candidate for involvement in the observed BBB permeability changes in 
diabetes.  Thus, we investigated the role of VEGF in STZ- and minocycline-induced 
changes in claudin-5.  
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Western analysis demonstrated that VEGF protein levels decreased in STZ-
treated diabetic rats.  Minocycline increased VEGF protein expression in both control 
and STZ-treated rats, with significance in the latter group.  This result is opposite to 
what we expected based on studies in the retina.  Harhaj et al. (2006) showed elevated 
VEGF-induced changes in tight junction proteins leads to increased permeability, and 
reduced VEGF prevents the permeability change.  Isoforms of VEGF can be diffusible 
or bound to the extracellular matrix.  VEGF165, the most studied isoform, is secreted but 
the majority is bound to the extracellular matrix (Ferrera et al, 2003).   Hollborn et al. 
(2010) demonstrated that minocycline promoted the expression of VEGF in retinal 
pigment epithelial cells.  Wasserman and Schlichter (2007) showed that minocycline 
decreased MMPs at the BBB, likely keeping the extracellular matrix relatively intact.  
Therefore, the inhibition of MMPs reduced the VEGF release from the basement 
membrane, perhaps explaining the increased levels of VEGF.  It is also important to 
remember that VEGF response is due to the interaction of a number of receptors and 
cofactors.  Thus, we looked at expression levels of the primary VEGF receptors and its 
inhibitory cofactor, SEMA 3A. 
  At the BBB, VEGF has two primary receptors and two co-receptors.  The 
interaction of the VEGF receptors, Flt-1 and Flk-1, with the neuropilin receptors dictates 
the cellular response induced by VEGF.  In our study, STZ did not have an effect on the 
VEGF receptors, Flt-1 and Flk-1.  However, minocycline significantly increased protein 
expression of Flt-1 in control animals and showed a similar trend in the STZ-treated 
animals.  Minocycline also increased protein expression of Flk-1 in the control group, 
but it did not have an effect on the receptor in STZ-treated animals.  Minocycline had no 
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significant effect on expression of the neuropilin receptors, NP-1 and NP-2, in either 
control or STZ groups.  Finally, the VEGF regulator, SEMA 3A, was decreased in both 
control and STZ-treated animals, although not statistically significant.     
VEGF-induced angiogenesis and permeability are regulated by a complex 
interaction of receptors, predominantly Flk-1 and the neuropilin receptors.  It has been 
proposed that the ratio of VEGF to SEMA 3A is a critical factor in driving permeability.  
Although not significant, we see a decrease in VEGF in the STZ-treated animals.  This 
decrease in VEGF would promote the SEMA 3A portion of the response, which is linked 
to an increase in permeability (Acevedo et al., 2008; Le Guelte et al., 2012).  This 
observation could explain the change in STZ-induced permeability.  Le Guelte et al. 
(2012) showed that this change is in part due to inhibition of serine phosphatase PP2A 
activity promoting a dissociation of VE-cadherin from adherens junctions.  An increase 
in Flt-1 and no change in Flk-1 in diabetic rats with minocycline treatment suggests that 
the “decoy receptor,” Flt-1, may be sequestering any VEGF that might be secreted, 
inhibiting its ability to bind to the Flk-1 receptor, which has the major role in inducing 
changes at tight junctions.  Previous studies have demonstrated that minocycline is able 
to decrease VEGF-induced smooth muscle cell migration in the vasculature by 
downregulating the Erk 1/2 and PI3K/Akt signaling pathways (Yao et al., 2004, 2007).  
VEGF is able to bind to the neuropilin receptors, and its binding enhances its ability to 
bind to and activate Flk-1 (Sulpice et al., 2008).    Last, minocycline decreased protein 
expression of the VEGF antagonist, SEMA 3A, in both control and STZ-treated animals, 
although not significant.  On its own, SEMA 3A is also a permeability factor (Acevedo et 
al., 2008).    Lower SEMA 3A levels due to minocycline treatment would result in greater 
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VEGF binding to neuropilin receptors, and consequently, smaller BBB permeability 
changes than normally in diabetic animals. 
 In conclusion, our study shows that minocycline is able to decrease permeability 
to sucrose, a low molecular weight molecule, in diabetic microvessels.  This 
permeability decrease coincides with an increase in protein expression of claudin-5.  
Minocycline is able to increase protein expression of VEGF in the diabetic group.  No 
change was observed in the Flk-1 receptor, but the Flt-1 receptor increased.  This 
increase in receptor expression suggests that VEGF is sequestered by Flt-1, and is 
prevented from binding Flk-1.  Thus, it is likely that the Flk-1 is not phosphorylated and 
subsequently, any signaling pathway that would lead to a permeability increase is not 
activated.  Although the protein expression of the neuropilin receptors increased in the 
diabetic group treated with minocycline, VEGF signaling is unlikely since there was no 
change in Flk-1.  Last, minocycline decreased protein expression of SEMA 3A, but not 
significantly.  It is possible to reduce permeability in diabetic microvessels through this 
route as well.  Therefore, minocycline is a potential therapeutic treatment for decreasing 
permeability at the BBB in diabetes. 
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Chapter 3:  The Potential Role and Regulation of VEGF in BBB Dysfunction    
Abstract 
 Diabetes is characterized by hyperglycemia, which can lead to various 
macrovascular and microvascular complications.  Microvascular complications are 
evident in retinal and renal pathologies.  Similar complications are evident in the brain 
microvasculature particularly in the blood-brain barrier (BBB), a specialized 
microvasculature composed of endothelial cells that interacts with various cell types in 
the brain.  Significant changes to the BBB occur in diabetes; however, the mechanisms 
leading to these changes are unknown.  This study focuses on the vascular endothelial 
growth factor (VEGF) signaling system, a potent pro-angiogenic and vascular 
permeability factor, as a potential mechanism for the observed BBB changes.  
Previously, we have shown a potential role of VEGF-based signaling for the observed 
BBB changes (Chapter 2).  In the present study, results showed changes in mRNA of 
VEGF and its receptors; however VEGF protein levels remained unchanged in diabetic 
animals.  Interestingly, protein expression of VEGF receptors and co-receptors as well 
as SEMA 3A, an antagonist of VEGF, did not change.   In this study, we investigated 
the possibility that altered abundance of microRNAs (miRNAs) might explain the 
discrepancy between our mRNA and protein data.  Protein expression of PLC-γ, a 
downstream signaling target of Flk-1, showed statistically significant changes within the 
diabetic groups.  Taken together, these results indicate that VEGF signaling could be 
based on the relative diabetic state as a result of the absence of insulin or other 
changes that occurred as a consequence of STZ toxicity. 
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Introduction 
Diabetes is a risk factor for vascular dementias and cardiovascular events such 
as stroke.  The exact mechanism behind the increased risk is unknown; however it is 
often linked with hyperglycemia and subsequent cerebral edema.  Increased peripheral 
vascular permeability and the development of vascular complications contribute to the 
morbidity and mortality of diabetes (Perrin et al., 2009).  There is now increasing 
evidence that the cerebral blood vessels are also compromised, and that this may 
contribute to the neurological problems associated with diabetes (Huber et al., 2006).  
Under normal circumstances brain homeostasis is regulated by the blood-brain barrier 
(BBB).  The BBB, a specialized microvascular structure comprised of endothelial cells 
held together by tight junctions, functions to protect the brain from toxins in the 
peripheral circulation, to allow nutrients to move from blood to brain, and to mediate 
waste efflux from the brain (Hawkins and Davis, 2005).  Overall, the BBB is important 
for the maintenance of the central nervous system.  Breakdown of the BBB can lead to 
changes in cognition and poor cardiovascular outcomes (Huber et al., 2006). 
Clinical studies have shown that diabetic patients have increased permeability of 
the BBB (Starr et al., 2003).  This permeability increase has been observed in 
experimental models of diabetes and has been associated with a decreased expression 
of tight junction proteins, particularly occludin and ZO-1 (Hawkins et al., 2007).  The 
change in permeability can be prevented by insulin acutely (Hawkins et al., 2007; Huber 
et al., 2006), but not chronically (Huber et al., 2006), and by using seasmol (VanGilder 
et al., 2009) or minocycline (Chapter 2).  Several factors have been linked to these 
changes including increased matrix metalloproteinase activity (Hawkins et al. 2007), 
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dyslipidemia (Ginsberg, 1999; Goldberg, 2001), and reactive oxygen species (VanGilder 
et al., 2009).  However, the exact mechanism of these changes is unknown.   Similar 
changes in tight junction expression at the blood-retinal barrier have been shown to be 
regulated by VEGF (Antonetti et al., 1998).   
The VEGF family consists of dimeric glycoproteins VEGF-A, -B, -C, -D, and 
placental growth factor (Olsson et al., 2006).  VEGF-A, the main and most studied, has 
several isoforms, with VEGF165 being the most abundant (Wirostko et al., 2008).  VEGF-
A is a modulator of both angiogenesis and permeability.   It exerts its effects by binding 
to membrane bound VEGF receptors-1 and -2 (Flt-1 and Flk-1, respectively) as well as 
the neuropilin receptors-1 and -2 (NP-1 and NP-2).  Flt-1 is thought to be a decoy 
receptor regulating VEGF/Flk-1 interaction, whereas Flk-1 regulates permeability in the 
kidney and eye as well as directly transmitting signals associated with pathological 
angiogenesis (Wirostko et al., 2008).  The binding of VEGF to the Flk-1 receptor can 
result in activation of several pathways leading to increased permeability, survival, 
migration, and proliferation (Holmes et al., 2007).  For stimulation of angiogenesis, 
simultaneous binding of VEGF to both Flk-1 and NP receptors is required (Sulpice et al., 
2008).  This interaction can be blocked by SEMA 3A, which binds to the NP receptors 
thereby blocking the VEGF binding site.  The presence of SEMA 3A does not however 
affect VEGF-induced permeability changes, but there is also evidence that SEMA 3A 
can induce permeability on its own (Acevedo et al., 2008). 
Previous studies have shown that the BBB is sensitive to VEGF (Fischer et al, 
2004; Argaw et al, 2009).  I hypothesized that VEGF signaling is also involved in BBB 
breakdown in diabetes.  We used an experimental model of diabetes to investigate 
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regulation of the VEGF signaling system at the BBB using real-time PCR, ELISA, and 
immunoblot techniques, and miRNA studies.    
 
Methods  
Animal Care 
Animal procedures were performed in strict accordance with the Institutional Animal 
Care and Use Committee, Marshall University.   Male Sprague-Dawley rats (Hilltop 
Laboratories, Scottdale, PA) were injected with either 65 mg/kg STZ (Sigma, St. Louis, 
MO) or 0.9% sterile saline.  Animals were maintained under a 12h-12h dark-light cycle, 
at ambient temperature of 22 ± 2o C, with food and water available ad libitum.  Animals 
were euthanized 14 days post-injection via an intramuscular injection of 1 mL/kg of a 
cocktail containing ketamine (71.5 mg/mL) and xylazine (5.7 mg/mL).  Blood samples 
were collected from the descending aorta and tested for glucose, ketones, and lipids 
with an analyzer (CardioChek PA, Polymer Technology Systems, Indianapolis, IN).  The 
blood samples were centrifuged and plasma samples were stored at -80°C.  Diabetic 
rats were divided into groups based on their blood glucose levels:  mild ≥ 300 mg/dl and 
high ≥ 400 mg/dl.   
Cerebral Microvessel Isolation  
Microvessels were isolated from rat brains as previously described (Hawkins et al, 
2007).  The final microvessel pellet was resuspended in either tissue extraction buffer 
(ThermoScientific, Rockford, IL) for protein extraction or TriReagent (Sigma, St. Louis, 
MO) for RNA isolation.  Protein was analyzed using bicinchoninic acid (BCA) protein 
assay kit (ThermoScientific, Rockford, IL).   
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Reverse Transciption and Real-time Polymerase Chain Reaction  
RNA was isolated via TriReagent following the manufacturer’s protocol (Sigma, St. 
Louis, MO), and samples were incubated with the complete reaction mixture from the 
iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, CA) to obtain cDNA.  Then cDNA was 
incubated with a reaction mixture containing iQ SYBR Green Supermix (Bio-Rad, 
Hercules, CA) and the appropriate forward and reverse primers of each gene listed in 
Table 3.1 (Invitrogen, Carlesbad, CA).   
ELISA  
Rat VEGF ELISA kits were purchased from RayBiotech, Inc (Norcross, GA).  All 
reagents and samples were brought up to room temperature prior to use.  Solutions, 
standards and samples were prepared as per protocol instructions. 
Western Blot Analysis of Immunoreactive Protein 
The levels of specific proteins were identified by Western blot analysis.  Protein samples 
(20 µg/well) were separated via SDS gel electrophoresis using 4-12% Bis-Tris gel 
(Criterion, Bio-Rad, Hercules, CA) followed by transfer to nitrocellulose paper.  Western 
blot analysis was performed using primary antibodies directed against VEGF, Flk-1, Flt-
1, and p-Flk-1 (Tyr 951,1175, and 1214),  NP-1, NP-2, and SEMA 3A (Santa Cruz 
Biotechnology, Santa Cruz, CA).  Antibodies directed against p-PI3K, PI3K, p-Akt, Akt, 
p-PLCγ, PLCγ, p-Erk 1/2, Erk 1/2, p-Src, Src, p-p38, and p38 were purchased from Cell 
Signaling Technology (Danvers, MA). Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) antibodies were used to normalize protein loading. The presence of protein 
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bound to each antibody was detected by horseradish peroxidase conjugated secondary 
antibody (GE Healthcare Bio-Sciences, Piscataway, NJ). Protein bands were detected 
by the enhanced chemiluminescence system (GE Healthcare Bio-Sciences, 
Piscataway, NJ). 
Extraction and Purification of microRNA (miRNA) 
A PreAnalytiX’s PAXgene® Blood miRNA Kit was used to extract the miRNA from blood 
samples from control and STZ animals.  Approximately 200 ng of miRNA was reverse 
transcribed to cDNA using Qiagen RT2 miRNA First Strand Kit.  Because over 300 
miRNAs have been identified in rats, Qiagen MAR-3100G miRNA 384 arrays was used 
to run each assay.  BioRAD iQTM SYBR® Green Supermix and RNAse-free water plus 
sample were used for the arrays.  Ct values were obtained after the data was analyzed 
on the ROCHE-480 Light Cycler using the Absolute Quantitative/2nd Derivative Max 
program.  Fold change data was analyzed using the SA Bioscience’s RT2 miRNA PCR 
Array Data Analysis program. Both Rnu6 and miR-16 were used as housekeeping 
genes.  Statistical analyses were performed using student’s t-test.  Fold change >3.0 
and <0.3 was used as cut-off for miRNAs up- or down-regulated respectively, and 
P<0.05 was used to indicate significance. 
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Primer Sequence (5’→3’) Forward/Reverse 
VEGF GCCAGCACATAGGAGAGATGAGC Forward 
VEGF CAAGGCTCACAGTGATTTTCTGG Reverse 
Flt-1 AGGAGAGGACCTGGAACTGTCTT Forward 
Flt-1 ATTCCTGGGCTCTGCAGGCATAG Reverse 
Flk-1 TAGCACGACAGAGACTGTGAGG Forward 
Flk-1 TGAGGTGAGAGAGATGGGTAGG Reverse 
NP-1 GGAGCTACTGGGCTGTGAAG Forward 
NP-1 ATGTCGGGAACTCTGATTGG Reverse 
NP-2 ACACAAGGAGCCATTTCCAG Forward 
NP-2 CGGATCCTGATGAAACGAGT Reverse 
SEMA 3A AAGGCCGGGCACTCTCAAG Forward 
SEMA 3A ACTCCTGGGTGCCCTCTCAACT Reverse 
GAPDH TCCACCACCCTGTGCTGTA Forward 
GAPDH ACCACAGTCCATGCCATCAC Reverse 
 
  Table 3.1.  Primers used for Real-Time PCR experiments 
 
61 
 
Results 
Blood Chemistries  
Table 3.2 shows blood characteristics and weights of control and diabetic animals.  
Blood glucose levels were significantly different in diabetic animals compared to 
controls.  These differences in blood glucose levels within the diabetic group prompted 
us to separate this group into mild and high glucose groups for subsequent 
experiments.  Ketone levels were significantly different between the diabetic groups as 
well as between control and high glucose animals.  Cholesterol, HDL, and triglyceride 
levels remained relatively unchanged in both control and diabetic animals.  Weight was 
significantly lower in animals with mild and high glucose levels at 7 and 14 days post-
injection compared to control (Table 3.3). 
STZ treatment increased VEGF and VEGF receptor mRNA expression 
To determine mRNA expression of VEGF and the VEGF receptor system, RNA from 
both control and STZ-treated rats was isolated (Figure 3.1).  Real-time PCR showed 
that mRNA expression of VEGF increased about 2.5 fold in the microvessels of STZ-
treated animals compared to control.  Additionally, expression of the VEGF receptors, 
Flt-1 and Flk-1, as well as the neuropilin receptors, NP-1 and NP-2, increased in 
diabetic rats.  SEMA 3A mRNA expression also increased in diabetic rats compared to 
control. 
VEGF protein levels remain unchanged 
To determine whether VEGF levels changed in diabetic versus control rats, protein from 
microvessels were isolated.  ELISA analysis (Figure 3.2A) showed that there was no 
change in VEGF protein levels in the microvessels of STZ-treated animals.  Additionally, 
plasma levels of VEGF did not change in diabetic animals versus control (Figure 3.2B).   
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Western analysis showed no appreciable change in VEGF in animals with mild or high 
glucose compared to control animals (Figure 3.3).   
VEGF receptor protein levels did not exhibit glucose-dependent changes 
Western analysis showed that protein levels of the VEGF receptors, Flt-1(Figure 3.4) 
and Flk-1 (Figure 3.5), did not change in the diabetic groups compared to control.    
Additionally, the co-receptor, NP-1 did not change in all the groups (Figure 3.6).  The 
VEGF modulator SEMA 3A, which competitively binds to the neuropilin receptors, 
remained relatively unchanged in diabetic animals compared to control (Figure 3.7). 
Circulating MicroRNA changes in diabetes 
MicroRNA studies showed an up-regulation of miR-330, -26b, -361, -139-5p, and let-7a 
and let-7c, and a down-regulation in miR-127 and -497.  These miRNAs are involved in 
insulin signaling as well as VEGF and its receptors (Table 3.4).   
No change in Flk-1 phosphorylation 
To determine whether the Flk-1 receptor was activated, we looked at three 
phosphorylation sites, tyrosine 951, 1175, and 1214, on the receptor that regulates the 
downstream signaling of VEGF.   Western analysis showed no changes in 
phosphorylation (Figures 3.8-3.10).   
Regulation of downstream targets of Flk-1  
To determine if the observed changes at the BBB was due to the activation of Flk-1, we 
examined downstream signaling targets at the three phosphorylation sites.  
Phosphorylation of 951 leads to activation of Src, which can subsequently lead to a 
permeability increase (Holmes et al., 2007).  However, in our animal model, expression 
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 Glucose 
(mg/dL) 
Ketones 
(mg/dL) 
Cholesterol 
(mg/dL) 
HDL Triglycerides 
Control 264 8.8 100 26 87 
Mild 
Glucose 
358* 17* 126 44† 177 
High 
Glucose 
487* 16* 110 39†† 152‡ 
* Kruskal-Wallis One-Way ANOVA on Ranks p=<0.001 
compared to control 
† Kruskal-Wallis One-Way ANOVA on Ranks p = 0.021 
compared to control 
†† Kruskal-Wallis One-Way ANOVA on Ranks p = <0.001 
compared to control 
‡ Kruskal-Wallis One-Way ANOVA on Ranks p = 0.025 
compared to control 
 
  Table 3.2.  Blood chemistry of control and diabetic animals.  (n=15 for control; n=9 for 
mild glucose; n=6 for high glucose) 
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 Day 1 (g) Day 7 (g) Day 14 (g) 
Control 329 368 389 
Mild Glucose 324.5 320* 317‡ 
High Glucose 327 313† 306†† 
* Kruskal-Wallis One-Way ANOVA on Ranks p = <0.001 
compared to control 
† One-Way ANOVA p = <0.001 compared to control 
‡ Kruskal-Wallis One-Way ANOVA on Ranks p = <0.001 
compared to control 
††  Kruskal-Wallis One-Way ANOVA on Ranks p = <0.001 
compared to control 
 
  
Table 3.3.  Weights of control and STZ-induced diabetic animals during the 14-
day time course.  (n=15 for control; n=9 for mild glucose; n=6 for high glucose) 
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of Src did not show any change (Figure 3.11).  Phosphorylation at tyrosine 1175 can 
result in either phosphorylation of PI3K, which leads to increased permeability, or 
phosphorylation of PLCγ, which results in changes in gene transcription and 
subsequent proliferation of endothelial cells (Holmes et al., 2007).  Our studies showed 
that total phosphorylation expression of PI3K or its downstream target, Akt, did not 
exhibit any change (Figures 3.12-3.13).  Interestingly, the ratio of p-PLCγ/PLCγ showed 
a statistically significant decrease between diabetic animals with high glucose (Figure 
3.14), but phosphorylation expression of Erk 1/2, the downstream target of PLCγ, did 
not significantly change (Figure 3.15).  Phosphorylation of Flk-1 at tyrosine 1214 can 
lead to the activation of p38 MAPK to induce actin reorganization and migration of 
endothelial cells (Holmes et al., 2007); however, our studies did not show any change in 
p38 protein expression (Figure 3.16).   
 
Discussion 
Increased BBB permeability has been observed in both clinical studies and in animal 
models of diabetes.  However, the mechanism of this permeability increase has not 
been elucidated.  Studies have shown that VEGF is a modulator of blood-retinal barrier 
permeability in a diabetic model of diabetes (Antonetti et al., 1998).  The present study 
focuses on VEGF as a modulator of BBB permeability due to its capability to act as a 
pro-angiogenic and permeability factor.  To determine if VEGF is involved in the 
observed changes in the BBB in diabetes, we initially looked at gene expression of 
VEGF and its receptors via real-time quantitative PCR.  Our results show that gene 
expression of VEGF, its receptors, and SEMA 3A increased in diabetic rats compared to 
control.  However, when protein expression was evaluated, there was no change in 
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VEGF levels in diabetic animals with mild or high glucose compared to the control 
group.  Microvessel-based VEGF can be found in two main locations:  1) within the cell 
itself or 2) sequestered in the matrix of the basement membrane, where it is bound via 
its heparin binding domain (Zhang et al., 2009) to glycosaminoglycan chains and other 
components of the extracellular matrix (Gabhann et al., 2009).  Under normal 
circumstances VEGF-A165 is synthesized by the cell and then released into the 
extracellular matrix.  Under conditions which promote basement membrane breakdown, 
VEGF is rapidly released allowing for repair.  Basement membrane disruption is a 
common feature in BBB breakdown, mediated via an elevation in MMP activity.  We 
have previously reported BBB breakdown in the STZ model paralleled by an increase in 
MMP activity (Hawkins et al., 2007).  It is thus possible that if extra VEGF is being 
made, it is being released at a rate that equals the rate of production, potentially via 
MMP-induced basement membrane degradation.  In fact, though not significant, there 
was a ~15% decrease in the levels of microvessel-related VEGF in the STZ animals.      
 Typically, a pathological event will up-regulate VEGF and its receptors.  Protein 
expression of the VEGF receptors, Flt-1 and Flk-1, and the co-receptor, NP-1, did not 
change in the diabetic groups compared to control.  There are potential mechanisms 
that might shed light to this observation.  VEGF and its receptors have been shown to 
increase during pathological events.  On the other hand, VEGF has also been shown to 
down-regulate receptor expression, despite an increase in receptor mRNAs (Wang et 
al., 2000).  Additionally, it is possible that receptors are being either degraded or 
sequestered into the cell.  Studies have demonstrated that VEGF stimulation was able 
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Figure 3.1.  Real-time PCR analysis.  Gene expression of VEGF, its receptors, co-
receptors, and SEMA 3A increased in STZ-induced diabetic animals compared to 
control (n=5). 
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Figure 3.2.  ELISA analysis of VEGF protein levels in cerebral 
microvessels and plasma of control and diabetic animals.  VEGF 
protein levels did not change in (A) microvessels or (B) plasma of either 
control or diabetic animals.  (n=23 for microvessels; n=8 for plasma) 
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Figure 3.3.  VEGF protein levels did not change in diabetic animals.  
VEGF protein levels did not change in diabetic animals with mild or high 
glucose levels compared to control. (one-way ANOVA; n=12 for control; n=8 
for mild; n=4 high) 
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Figure 3.4.  Flt-1 protein expression did not change.  Western analysis 
showed that Flt-1 protein expression did not change in diabetic animals with 
mild or high blood glucose levels compared to control animals. (one-way 
ANOVA; n=11 for control; n=6 for mild; n=5 for high) 
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Figure 3.5.  Flk-1 protein expression did not change diabetic animals.  
There was no change in Flk-1 protein levels in diabetic animals with mild or 
high blood glucose levels compared to control animals. (one-way ANOVA; 
n=14 for control; n=9 for mild; n=5 for high) 
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Figure 3.6.  No change in NP-1 expression in diabetic animals.  No change 
was observed in NP-1 protein levels in diabetic animals with mild or high blood 
glucose levels compared to control animals.  (one-way ANOVA; n=10 for 
control; n=5 for mild; n=5 for high) 
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Figure 3.7.  No change in SEMA 3A expression.  Western analysis showed 
no change SEMA 3A protein levels in diabetic animals with mild or high blood 
glucose levels compared to control animals.  (one-way ANOVA; n=11 for 
control; n=6 for mild; n=5 for high) 
SEMA 3A 120 kDa  
 
GAPDH 37 kDa 
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MiRNA p-value Fold Change Angiogenic 
Target 
miR-330 0.004 27.21 increase SEMA 3A 
NP-2 
miR-139-5p 0.045 3.01 increase Rho-kinase 2 
miR-497 0.013 4.70 decrease Flk-1 
let-7a 0.030 3.45 increase TGF-β receptor 
let-7c 0.023 3.43 increase TGF-β receptor 
miR-361 0.023 3.99 increase VEGF-A 
miR-127 0.031 5.93 decrease VEGF-A 
NP-1 
Table 3.4.  MicroRNAs involved in VEGF signaling. 
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Figure 3.8.  No change in p-Flk-1 (tyrosine 951) protein expression in 
STZ-induced diabetic animals.  Western analysis showed that 
phosphorylation of Flk-1 at tyrosine 951 did not change in diabetic animals 
compared to control.  (one-way ANOVA; n=11 for control; n=6 for mild; n=5 for 
high) 
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Figure 3.9. No change in p-Flk-1 (tyrosine 1175) protein expression in STZ-
induced diabetic animals.  Phosphorylation of Flk-1 at tyrosine 1175 did not 
change in STZ animals compared to control. (one way ANOVA; n=10 for control; 
n=5 for mild; n=5 for high) 
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Figure 3.10.  No change in p-Flk-1 (tyrosine 1214) protein expression in STZ-
induced diabetic animals.  Phosphorylation of Flk-1 at tyrosine 1214 did not 
change in STZ animals compared to control.  (one-way ANOVA; n=10 for control; 
n=5 for mild; n=5 for high) 
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Figure 3.11.  No change in Src protein expresssion in STZ-induced diabetic 
animals.  Western analysis showed that global phosphorylation did not change in 
Src, the downstream target of Flk-1 at tyrosine 951, in diabetic animals compared to 
control.  (n=8 for control; n=4 for mild; n=4 for high) 
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Figure 3.12.  No change in protein expression of PI3K in STZ-induced diabetic 
animals.  Phosphorylation of PI3K, the downstream target of Flk-1 at tyrosine 1175, 
did not change in diabetic animals compared to control.  (n=13 for control; n=7 for 
mild; n=6 for high) 
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Figure 3.13.  No change in protein expression of Akt in STZ-induced diabetic 
animals.  Phosphorylation of Akt, the downstream target of Flk-1 at tyrosine 1175, 
did not change in diabetic animals compared to control.  (n=15 for control; n=9 for 
mild; n=6 for high) 
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Figure 3.14.  Protein expression of PLCγ in STZ-induced diabetic animals.  
Western analysis showed that there was a significantly greater phosphorylation of 
PLCγ in diabetic animals with mild glucose levels compared to diabetic animals 
high blood glucose levels.  (n=12 for control; n=6 for mild; n= 6 for high) 
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Figure 3.15.  No change in protein expression of Erk 1/2 in STZ-induced 
diabetic animals.  Western analysis showed that there was no change in 
phosphorylation of Erk 1/2 in diabetic animals compared to control. (n=14 for 
control; n=9 for mild; n=5 for high) 
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Figure 3.16.  No change in protein expression of p38 in STZ-induced diabetic 
animals.  There was no change in phosphorylation of p38 in diabetic animals 
compared to control.  (n=10 for control; n=6 for mild; n=4 high) 
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to decrease Flk-1 levels at the plasma membrane through modification and degradation 
(Ewan et al., 2006).   
Another explanation for the lack of effect of STZ treatment on Flk-1 expression is 
that receptor levels are decreased in the post-natal brain (Kremer et al., 1997).  
Therefore, it is possible that Flk-1 receptor expression is low in this diabetic model.  
Maturation of Flk-1 involves glycosylation, resulting in 200 and 230 kDa forms of the 
receptor.  However, we were unable to detect Flk-1 at these molecular weights.  A 
fraction of the NP-1 receptor can be modified with either heparin or chondroitin sulfate, 
and this modification is able to post-transcriptionally regulate Flk-1 expression (Shintani 
et al., 2006).  Although NP-1 protein levels did not change, it is possible that there is 
enough modification of NP-1 receptors that could influence Flk-1 expression.  VEGF 
has been shown to mediate Flk-1/NP-1 complex (Soker et al., 2002).  Since VEGF 
protein levels did not change, then the Flk-1/NP-1 complex is less likely to form.  
No change was observed in SEMA 3A protein levels in the diabetic animals.  
Furthermore, the VEGF/SEMA 3A ratio was unchanged between control and diabetic 
groups.  An imbalance in this ratio in favor of VEGF would likely lead to activation of 
several pathways involved in angiogenesis and permeability, such as migration and 
proliferation.  SEMA 3A is also a permeability factor acting through the neuropilin 
receptor (Acevedo et al., 1998).  Therefore, SEMA 3A competes with VEGF in binding 
with the neuropilins.  Additionally, VEGF has been shown to internalize the NP-1 in 
endothelial cells when competing with SEMA 3A (Narazaki and Tosato, 2006).  
Although the VEGF/SEMA 3A ratio did not change, this result could offer explanation for 
no change in NP-1 protein levels. 
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Although mRNA levels of VEGF, its receptors, and SEMA 3A increased in 
diabetic animals compared to control, we did not see any changes at the protein level.  
Recent studies have shown that circulating microRNA can play a significant role in 
diabetes (Guay et al., 2011; Rottiers et al., 2012).  MicroRNA are short, non-coding, 
single-stranded RNAs, which regulate expression mRNA either by 1) complete 
homology resulting in mRNA degradation or 2) imperfect homology leading to 
translation repression.  Circulating miRNAs that were significantly altered in STZ-
induced diabetic rats include miRNAs which regulate insulin receptors and insulin 
binding proteins.  In addition, there were miRNAs which could be involved in regulating 
VEGF signaling.  There was a significant up-regulation of miR-361 and a down-
regulation of miR-127, both of which target VEGF.  Although there was no change in 
VEGF protein levels, these miRNAs may be regulating VEGF expression.  Additionally, 
there was an up-regulation in miR-330, -26b, -let-7a/c, and -139-5p.  SEMA 3A is a 
potential target for miR-330, and up-regulation of miR-330 may contribute to the 
mismatch between our SEMA 3A mRNA and protein measurements.  There was also a 
down-regulation in miR-497, which targets Flk-1.  An increase in Flk-1 protein 
expression would be expected.  These discrepancies between mRNA and protein could 
be due to miRNA interaction with AU-rich element binding proteins (ARE-BPs), which 
together can regulate gene expression (Chang et al., 2011).  Additionally, there could 
be Dicer silencing, which would lead to total reduction of miRNAs and impairment of 
VEGF-induced cellular processes (Suarez et al., 2008; Chang et al., 2011). 
STZ treatment did not change Flk-1 phosphorylation at any of the tyrosine 
residues.  The neuropilins can regulate Flk-1, which could explain the lack of Flk-1 
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phosphorylation and/or lack of VEGF-mediated formation of Flk-1/NP-1 complex.  
Although Flk-1 phosphorylation did not change, we continued to look at downstream 
targets of Flk-1.  Phosphorylation of PI3K and Akt via activation of p-Flk-1 (tyrosine 
1175) did not change in the diabetic groups compared to the control.  Even though this 
pathway has been shown to increase permeability in endothelial cells, it is not surprising 
that phosphorylation of these downstream targets did not change since pFlk-1 levels did 
not change.  However, phosphorylation of PLCγ, also via activation of Flk-1 (tyrosine 
1175) was significantly increased in diabetic animals with mild glucose levels compared 
to animals with high glucose (P<0.012), but neither group showed significant difference 
with the control animals.  This pathway stimulates proliferation of endothelial cells, 
which is important in angiogenesis, but it can also lead to eNOS activation and 
subsequent permeability.  Additionally, permeability can occur via PLCγ- dependent 
influx of calcium (Holmes et al., 2007).  However, Erk 1/2, the downstream target of 
PLCγ, did not change in the diabetic group versus control.  This is not surprising since 
Erk 1/2 activity can be regulated by other proteins such as Ras (Hood et al., 2003) and 
reactive oxygen species (Wang et al., 2004).  Ras has also been shown to mediate 
VEGF expression in Ras-induced Erk and HIF-1α activation (Wang et al., 2004).  To 
complicate matters, Ras activation is also dependent on integrins, and these integrins 
can coordinate signaling pathways with VEGF (Hood et al., 2003).  Activation of Flk-1 
(tyrosine 951 and 1214) also did not yield changes in Src and p38 MAPK, respectively, 
in the diabetic groups compared to control.  A study by Kawamura et al. (2008) showed 
that activation of p38 MAPK required both Flk-1 and NP-1 receptors.  In our model, 
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neither receptor showed any change in diabetic versus control groups. Therefore, it is 
unlikely that p38 MAPK is involved in BBB permeability in diabetes.   
Although there was an increase in gene expression of VEGF, its receptors, and 
SEMA 3A, our study showed that protein levels did not change.  Protein expression of 
the components of the VEGF signaling system could be regulated by the abundance of 
specific miRNAs.  In addition, there was no change in the phosphorylation status of the 
Flk-1 receptor.  However, we were able to show a significant increase in PLCγ 
phosphorylation between the two subgroups of the STZ-treated animals.  Therefore, the 
regulation of VEGF and its signaling pathways may, in part, be a mechanism for the 
observed permeability increase in this diabetic animal model. 
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Chapter 4:  Discussion and Conclusions 
Discussion 
Diabetes is a significant problem in the United States, and complications include 
retinopathy, cardiovascular disease, peripheral artery disease, nephropathy, and 
neuropathy (Bonora et al., 2004; Pambianco et al., 2006).  Many of these complications 
are linked to microvascular pathologies.  Diabetic patients are at risk for 
cerebrovascular disease and neurodegeneration, and research has been aimed at the 
role of the blood brain barrier (BBB) in this process.  Several studies indicate that these 
complications can arise from the loss of integrity of the BBB (Abbott, 2002; Zlokovic, 
2008).  Thus, the BBB is unable to effectively maintain its barrier characteristics and 
becomes “leaky.”  This leakiness is associated with decreased expression of tight 
junction proteins, which serve to keep the endothelial cells of the BBB in close contact 
and restrict paracellular transport (Hawkins et al., 2007).   The first part of the study was 
to determine if the molecular changes at the BBB could be attenuated by minocycline, a 
tetracycline derivative.  Furtherermore, I hypothesized that VEGF plays a role in 
minocycline treatment.  VEGF is a potent angiogenic and permeability factor that has 
been implicated in vascular complications at the blood-retinal barrier in diabetes 
(Antonetti et al., 1998).  Minocycline has been shown to have an inhibitory effect on 
VEGF.  The aim of the second part of the study was to evaluate the potential role of 
VEGF in diabetic BBB dysfunction.   
Minocycline Studies 
 The STZ model of diabetes is a well-studied model, and we were able to show 
that diabetic animals were hyperglycemic and exhibited increased ketone levels, which 
are characteristics of TID.   Additionally, BBB integrity is compromised in diabetes.  
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Therefore, we hypothesized that minocycline would attenuate the observed BBB 
changes in diabetes.  We were able to show that minocycline does not affect blood 
glucose levels or brain weights of these animals, suggesting that the drug does not 
affect diabetes itself.  Studies have shown that minocycline reduced infarct volumes in 
MCAO models of ischemia (Yrjanheikki et al., 1999; Nagal et al., 2008; Matsukawa et 
al., 2009).  On the other hand, treatment with minocycline increased infarct volumes in 
hypoxia-ischemia studies (Tsuji et al., 2004).  These conflicting observations might be 
due to start of treatment times, as the above studies reported treatment prior to 
ischemic events, and duration of minocycline treatment.  In our study, we treated the 
animals with minocycline seven days after STZ injection in order to mimic a long term 
treatment.  Minocycline significantly decreased BBB permeability to sucrose in both 
control and STZ-treated animals.  Because previous studies in the laboratory have 
reported a decrease in tight junction protein expression in this animal model in 
conjunction with increased permeability (Hawkins et al., 2007), we predicted that 
minocycline might exert its effects on these tight junction proteins.  Treatment with 
minocycline had no effect on occludin and ZO-1 protein expression; however, 
minocycline significantly increased claudin-5 protein expression in both control and 
STZ-treated animals.  This observation was interesting because claudin-5 is considered 
to be the primary seal for tight junctions (Hawkins and Davis, 2005).  Minocycline may, 
in part, function to improve claudin-5 expression.  However, the mechanism of this 
increase in expression is not known.  Claudin-5 can be regulated by different 
mechanisms, such as storage, recycling, post-translational modification, and inhibition 
of specific signaling pathways such as the PKC pathway.  Furthermore, MMP activity 
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also affects claudin-5 expression.  It would be interesting to investigate these various 
avenues to determine how claudin-5 is regulated with minocycline treatment. 
The next step was to determine if VEGF is involved in this minocycline-induced 
increase in claudin-5.  Previous studies have shown that VEGF regulates claudin-5 
expression (Argaw et al., 2009).  Furthermore, minocycline is able to promote VEGF 
expression (Hollborn et al., 2010).  We did not see any change in VEGF protein 
expression in control and diabetic animals.  However, we were able to show that VEGF 
significantly increased in STZ-treated animals with minocycline, and a similar trend was 
observed in control animals treated with minocycline.  This increase in VEGF may be 
due to a decrease in MMP expression and activity since minocycline has been shown to 
decrease MMPs (Wasserman and Schlichter, 2007).  MMPs degrade the extracellular 
matrix, and previous work in the laboratory demonstrated an increase in MMP activity in 
STZ-treated animals (Hawkins et al., 2007).  The observed increase in VEGF levels with 
minocycline treatment suggests that the extracellular matrix is relatively intact and the 
majority of VEGF is bound to it.  Future experiments could investigate whether 
minocycline treatment decreases MMP activity in these animals.  
We also found a significant increase in Flt-1 in control animals treated with 
minocycline, and observed a similar trend in the minocycline-treated diabetic animals.  
Interestingly, Flk-1 protein expression did not change with minocycline treatment, and 
neither did the neuropilin receptors.  Flt-1 is a decoy receptor, and may be scavenging 
any VEGF that is secreted and thus inhibiting VEGF from binding the Flk-1 receptor.  
Inhibiting VEGF binding would prevent the activation of downstream signaling pathways 
that would lead to a permeability increase.  It would be interesting to see if these 
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signaling pathways affect claudin-5 expression in both control and minocycline-treated 
diabetic animals.   
STZ Studies 
VEGF increased upon minocycline treatment in diabetic animals (Chapter 2).  
Therefore, we studied the effects VEGF signaling might have on diabetes.  
Furthermore, studies have demonstrated that VEGF can induce a permeability increase 
and a decrease in tight junction expression in the blood vessels of the diabetic eye 
(Antonetti et al., 1998).  We were able to show that gene expression of VEGF, its 
receptors, and its endogenous antagonist, SEMA 3A, increased in STZ-treated rats 
compared to control in both cerebral microvessels and whole brain samples.  VEGF and 
VEGFR (Flt-1 and Flk-1) mRNA expression was higher in whole brain samples than in 
cerebral microvessels.  This result is expected since VEGF and its receptors are 
present in other cell types in the brain (McCloskey et al., 2008).  An increase in VEGF 
and Flk-1 mRNA expression has been demonstrated in other studies (Hoehn et al., 
2002).  However, we found that protein levels of VEGF did not change in the 
microvessels or plasma of either group.  This result was unexpected, as we would have 
expected an increase in VEGF protein levels in the diabetic brain microvasculature.  
Plate et al. (1992) demonstrated a low steady state level of expression of VEGF in 
blood vessels in the normal brain.  VEGF expression is up-regulated in various 
pathological events.  Since we observed an increase in mRNA expression of 
components of the VEGF signaling system, but no change at the protein level, we 
speculated that VEGF may undergo translational modification or that VEGF mRNA is 
regulated.  In collaboration with Dr. Santanam’s laboratory, we studied the potential 
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regulation of VEGF via microRNAs.  MicroRNAs are single stranded RNA that regulate 
expression of mRNA.  If the miRNA has 100% homology to the mRNA, then 
degradation of the mRNA occurs.  If there is partial homology, the mRNA undergoes 
translation repression.  Results indicate that up-regulation of miR-361 and down-
regulation of miR-127 in diabetic animals could offer an explanation as to why VEGF did 
not change in this model of diabetes.  miRNA-361 and -127 are known miRNAs that 
target VEGF mRNA.  Furthermore, VEGF may be bound to the extracellular matrix in 
our model, which may also explain why we did not see any change in VEGF protein 
expression in either the microvessels or plasma.  Additionally, other cell types, such as 
astrocytes, are able to secrete VEGF.  Thus, additional experiments would be needed 
to evaluate VEGF protein levels in the extracellular matrix and astrocytes.  
Interestingly, we also did not see any change in protein expression of the VEGF 
receptors, Flt-1, Flk-1 and NP-1.  In the normal brain microvasculature, Flk-1 is down-
regulated due to a decrease in angiogenesis post-natally (Kremer et al., 1997).  We 
speculated that receptor expression would increase in the diabetic brain.  An increase in 
Flk-1 protein expression was observed in STZ-treated retinas (Hammes et al., 1998).   
Additionally, it has been shown that VEGF is capable of up-regulating both mRNA and 
protein expression of Flk-1 (Shen et al., 1998).  However, our results are not fully 
consistent in what has been reported in the literature.    Flk-1 undergoes glycosylation, 
and we were able to show Flk-1 expression at 150 kDa, which is the immature receptor.  
Intermediate glycosylated and mature Flk-1 receptor are present at 200 and 230 kDa, 
respectively.  As the receptor undergoes glycosylation, it will move to the plasma 
membrane of the cell.  We were not able to observe the fully mature and functional 
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receptor, which may offer an explanation for the lack of change in receptor expression 
at the two-week time point.  We were, however, able to measure the activated receptor 
via its phosphorylation.  Therefore, it would be beneficial to extend the time point to see 
if there are receptor changes.  The Flt-1 receptor has higher affinity for VEGF than Flk-
1, and acts as adecoy receptor to sequester VEGF (Ferrara et al., 2003; Cebe-Suarez 
et al., 2006).    Studies have shown that Flt-1 protein expression increased in intraretinal 
vessels in proliferative diabetic retinopathy (Smith et al., 1999).  Additionally, it has been 
reported that VEGF is a major stimulus for Flt-1 up-regulation, especially in tumor 
angiogenesis (Barleon et al., 1997).  However, VEGF levels did not change in STZ-
induced diabetes, and may explain the lack of increase in Flt-1 expression.   
 The neuropilins function as co-receptors for VEGF signaling.  We showed that 
there was no change in NP-1 protein expression.  We were unable to show NP-2 
expression.  NP-2 also functions to promote VEGF-stimulated pro-angiogenic activity.  
Like NP-1, NP-2 can increase Flk-1 phosphorylation.  It would be important to look at 
NP-2 expression in this model.  An important question to ask is if NP-1 and NP-2 levels 
differ in this model, and if so, how does that affect VEGF signaling?  NP-1 and NP-2 are 
primarily expressed at the arterial and venous ends, respectively (Sulpice et al., 2008).  
It is possible that the level of enhanced VEGF signaling is dependent on the location of 
these co-receptors.  Furthermore, it would be interesting to examine if there are different 
affinities for Flk-1 binding between NP-1 and NP-2. 
 SEMA 3A is a ligand for the neuropilin receptors, and a competitive antagonist of 
VEGF.  When it binds to the neuropilin receptors, it inhibits VEGF-mediated 
angiogenesis but can also induce permeability (Acevedo et al., 2008).  We did not see 
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any change in SEMA 3A expression in our diabetic animals.  Furthermore, we did not 
see changes in the VEGF:SEMA 3A ratio.  If the ratio had changed in favor of VEGF, it 
is possible that VEGF-induced signaling pathways might be more evident in this model.  
It would be of interest to study SEMA 3A-induced permeability if the ratio had changed 
in favor of SEMA 3A.  Once SEMA 3A binds to the neuropilins, it must form a complex 
with plexin A1, the signaling receptor for semaphorins.  However, we were unable to 
detect the plexin A1 protein expression in our model; however, it is not known if it is 
absent altogether or if it was due to limitation of the antibody.   
 The lack of any observed changes in VEGF and its receptors prompted us to 
look at how the VEGF signaling system is regulated.  In collaboration with Dr. 
Santanam, we investigated whether expression of VEGF is modulated by microRNAs.  
Although not entirely complete, these results indicate that microRNAs might play an 
important part in regulating the VEGF signaling system.  In particular, the up-regulation 
of miR-361 and the down-regulation of miR-124 are likely indicators of how VEGF 
expression is modulated.  One miRNA may be more effective in regulating VEGF 
expression due to a closer match in homology.  The studies of the miRNAs are 
incomplete, and further investigation is needed to determine the role other miRNAs play 
in VEGF signaling.   
 Finally, we looked at phosphorylation of Flk-1 and the downstream targets of its 
signaling pathways.  We looked at three phosphorylation sites (tyrosine 951, 1175, and 
1214), but were unable to see any significant changes in the total phosphorylation.  
However, it appears that there is a trend for an increase in phosphorylation for all sites 
in diabetic animals with mild blood glucose, and a decrease in phosphorylation for all 
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sites in diabetic animals with high blood glucose.  This result could mean that in mildly 
diabetic animals signaling pathways are activated, but by the time diabetes is at 
uncontrolled and high glucose levels, the Flk-1signaling pathways are overwhelmed.  
We looked at downstream targets of the Flk-1 phosphorylation sites.  We did not see 
any changes in PI3K and Akt, the downstream target of tyrosine 1175.  This result was 
somewhat unexpected because Akt will lead to the activation of eNOS to induce 
vascular permeability.  However, we did see a significant change in phosphorylation of 
PLCγ, another downstream target of tyrosine 1175.  To our knowledge, this result is a 
novel finding.  However, a downstream target of PLCγ, Erk 1/2, did not exhibit any 
changes in phosphorylation.  This observation is not discouraging since Erk 1/2 
activation can be modulated by other signaling molecules, such as Ras.  This change in 
PLCγ is of particular interest because this is a known pathway of VEGF-induced tight 
junction regulation.  Inhibition of PLCγ activity leads to a hyperphosphorylation of tight 
junction proteins (Ward et al., 2002).  This hyperphosphorylation is believed to be due to 
PKCα/β regulation of tight junction proteins.  It would be beneficial to explore this 
avenue as a permeability increase could be a multi-pathway event.  Last, we did not see 
any changes in Src and p38, the downstream targets of tyrosine 951 and 1214, 
respectively.  
 It must also be remembered that we are looking at a single time point in a 
dynamic process.  Changes in the expression and activation levels of the VEGF system 
are likely to be modulated throughout the time of the disease.  Thus, future studies 
would probably benefit from looking at multiple time points and perhaps concentrating 
on either mild or high blood glucose levels. 
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Conclusions 
 Vascular permeability and a decrease in tight junction protein expression are 
evident in diabetes.  My results show that the increased permeability can be attenuated 
by the treatment of minocycline.  The decreased permeability was in conjunction with an 
increase in claudin-5 protein expression, known as the primary seal of the tight junction.  
These results show promise for pharmacological treatment of cerebrovascular 
complications of diabetes.  It has been shown in these studies that VEGF protein 
expression increased in diabetic animals upon minocycline treatment, perhaps making 
VEGF more available.  Thus, we wanted to further investigate VEGF in the observed 
BBB changes in diabetes.  The mechanism of increased permeability had not been 
elucidated in the literature, but studies have been shown that VEGF is implicated in 
vascular permeability in the diabetic eye.  Therefore, we looked to see if VEGF is 
involved in the vascular permeability.  Although VEGF and its receptors did not exhibit 
any changes at the protein level, we did observe a significant change in one of the 
downstream targets, PLCγ, which is involved in gene expression and proliferation of 
endothelial cells.  Although the mechanism is not complete, this result is a starting point 
to further investigate the role of the PLCγ signaling system in vascular permeability. 
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acetylcholine receptor and MMP-2/9 pathway mediate the proangiogenic effect of 
nicotine in human retinal endothelial cells.  Invest. Ophthalmol. Vis. Sci, June 16, 2010 ; 
doi:10.1167/iovs.10-5461. 
 
Herdman, M., Marcelo, A., Huang, Y., Niles, R.M., Dhar, S., and Kiningham, K.K.  
(2006).  Thimerosal Induces Apoptosis in a Neuroblastoma Model via the c-Jun N-
Terminal Kinase Pathway.   Toxicological Sciences, 92(1): 246-53. 
 
Abstracts: 
 
June 2012:  Marcelo, A. and Egleton, R.  The Role and Regulation of Vascular  
Endothelial Growth Factor (VEGF) at the Blood-Brain Barrier in a Rat 
Model of Diabetes.  Selected for Oral Presentation at the Gordon 
Research Seminar and Poster Presentation at the Gordon Research 
Conference, Colby Sawyer College, New London, NH. 
 
November 2011:  Furby, R., Shah, P., Marcelo, A., Cook, C., Egleton, R., and  
Santanam, N.  Circulating MicroRNAs Regulating Insulin Signaling in 
Type I Diabetic Rat Model.  Selected for Poster Presentation at the 
Annual Biomedical Research Conference for Minority Students, St. 
Louis, MO. 
 
November 2011:  Shah, P.,  Furby, R., Marcelo, A., Egleton, R., Cook, C., and  
Santanam, N.  Circulating miRNAs Regulating Angiogenesis Signaling 
in Type 1 Diabetic Rat Model.  Selected for Poster Presentation at the 
Annual Biomedical Research Conference for Minority Students, St. 
Louis, MO. 
 
July 2011:  Levin-Nielson, E., Marcelo, A., and Egleton, R.  Regulation of Vascular  
Endothelial Growth Factor Signaling (VEGF) in the Choroid Plexus (CP) in 
Diabetes.  Selected for Poster Presentation at the 10th Annual WV-INBRE 
Summer Research Symposium, Marshall University, Huntington, WV. 
 
July 2011:  McNeel, B.S., Proper, N.A., Marcelo, A.J., and Egleton, R.D.  Effect of  
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Minocycline (MIN) on Tight Junction Proteins of the Choroid Plexus (CP).   
Selected for Poster Presentation at the 10th Annual WV-INBRE Summer 
Research Symposium, Marshall University, Huntington, WV. 
 
July 2011:  Furby, R., Shah, P., Kocher, C., Cook, C., Marcelo, A., Egleton, R., and  
Santanam, N.  MicroRNA Involvement in Type I Diabetic Rat Models.  
Selected for Poster Presentation at the 10th Annual WV-INBRE Summer 
Research Symposium, Marshall University, Huntington, WV. 
 
May 2011:  Marcelo, A.J., and Egleton, R.D.    Vascular Endothelial Growth Factor  
(VEGF) Signaling and its Potential Role at the Blood Brain Barrier in 
Diabetes.  Selected for Poster Presentation at the XXVth International 
Symposium on Cerebral Blood Flow, Metabolism, and Function & Xth 
International Conference on Quantification of Brain Function with PET, 
Barcelona, Spain. 
 
March 2011:  Marcelo, A., and Egleton, R.  Modulation of the Blood Brain Barrier  
(BBB) by Vascular Endothelial Growth Factor (VEGF) in Diabetes.  
Selected for Poster Presentation at the 23rd Annual Research Day, 
MUSOM, Huntington, WV.  Winner for best basic science poster 
presentation 
 
June 2010:  Marcelo, A., and Egleton, R.  The Potential Role of Vascular Endothelial  
Growth Factor (VEGF) at the Blood Brain Barrier in Diabetes.  Gordon-  
Kenan Research Seminar on Barriers of the CNS, Colby-Sawyer College, 
New London, NH. 
 
June 2010:  Marcelo, A., and Egleton, R.  The Potential Role of Vascular Endothelial  
Growth Factor (VEGF) at the Blood Brain Barrier in Diabetes.  Gordon 
Research Conference on Barriers of the CNS, Colby-Sawyer College, 
New London, NH. 
 
March 2010:  Marcelo, A., and Egleton, R.  The Potential Role of Vascular Endothelial  
Growth  Factor (VEGF) in the  Diabetic Brain Microvasculature.  Selected 
for Poster Presentation at the 22nd  Annual Research Day, MUSOM, 
Huntington, WV; Winner for best basic science poster presentation 
.   
October 2009:  Marcelo, A., and Egleton, R.  The Role of VEGF Signaling in the  
Modulation of Diabetic Brain Vasculature.  Society of Neuroscience 
Meeting, Chicago, IL. 
 
October 2008:  Marcelo, A., and Egleton, R.  Blood Brain Barrier Dysfunction in a Rat  
Streptozotocin Model of Diabetes.  University of Kentucky 
Cardiovascular Research Day, Lexington, KY. 
 
June 2008:  Marcelo, A., and Egleton, R.  Expression of Angiogenic Regulatory  
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Receptors at the Blood Brain Barrier.  Gordon Research Conference:  
Barriers of the CNS, Tilton, NH 
 
August 2007:  Hunter, V., Silvis, A., Marcelo, A., and Kiningham, K.  N-Acetyl-L- 
Cysteine (NAC) Enhances All-Trans Retinoic Acid (ATRA)-Mediated 
Differentiation through Modulation of Retinoid Receptor Transcriptional 
Activity.  2007 WV-INBRE Summer Research Symposium, Huntington, 
WV. 
 
November 2006:  Kiningham, K., Spitz, D., Cook, C., and Marcelo, A.  Upregulation of  
Manganese Superoxide Dismutase mRNA, Protein and Activity by All-
Trans Retinoic Acid (ATRA):  Potential Roles of NFκB and the Retinoic 
Acid Receptor-α – 13th Annual Society for Free Radical Biology and 
Medicine Meeting, Denver, CO. 
 
November 2006:  Asbury, M., Tassone, M., Marcelo, A., Kiningham, K.  Acute  
Dopamine Stimulation in SK-N-MC Neuroepithelioma Cells Causes 
Activation of the Redox-Sensitive AP-1 Transcription Factor, Oxidative 
Stress, and Apoptosis– 13th Annual Society for Free Radical Biology 
and Medicine Meeting, Denver, CO.  
 
March 2006: Marcelo, A., Herdman, M., Cook, C., Kiningham, K. 
N-acetylcysteine (NAC) and Trolox Attenuate Thimerosal-Induced 
Oxidative Stress and Apoptosis – Selected for Poster Presentation at 
the 19th Annual Research Day, MUSOM, Huntington, WV; Winner for 
best basic science poster presentation 
 
August 2005: Davis, T., Cook, C., Humphrey, M., Marcelo, A., Tassone, M., Kiningham, 
K., Spitz, D.  Upregulation of Manganese Superoxide Dismutase Protein 
and Activity by All-trans Retinoic Acid (ATRA):  Potential Roles for NFκB 
and Retinoic Acid Receptors (RAR) – 4th Annual WV-INBRE Summer 
Research Symposium, Marshall University, Huntington, WV 
 
April 2005: Marcelo, A., Cook, C., Humphrey, M., Stewart, J., Kiningham, K. 
Antioxidants Block Thimerosal-Induced Stress Response and Attenuate 
Cellular Damage in a Human Neuroblastoma Cell Line (SK-N-SH) – 
Poster presentation at the 15th Annual Sigma Xi Research Day, Marshall 
University, Huntington, WV 
 
March 2005: Marcelo, A., Cook, C., Humphrey, M., Stewart, J., Kiningham, K. 
Antioxidants Block Thimerosal-Induced Stress Response and Attenuate 
Cellular Damage in a Human Neuroblastoma Cell Line (SK-N-SH) – 
Selected for Oral Presentation at the 18th Annual Research Day, 
MUSOM, Huntington, WV; Winner for best basic science oral 
presentation 
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April 2004: Marcelo, A., Cook, C., Humphrey, M., Kiningham, K. 
All-trans Retinoic Acid (ATRA) Protects Against Cisplatin-Mediated 
Apoptosis – Poster presentation at the 14th Annual Sigma Xi Research 
Day, Marshall University, Huntington, WV 
 
Extracurricular Activities 
March 2012 Volunteer at fourth annual Brain Expo at Marshall University.  
Presented interactive station to teach elementary school 
children about the retina at Marshall University's Brain Expo 
as part of a global Brain Awareness campaign organized by 
the Dana Alliance for Brain Initiatives 
 
March 2011 Volunteer at third annual Brain Expo at Marshall University.  
Presented interactive learning station about reflexes to area 
school children as part of International Brain Awareness 
Week. 
 
May 2010-April 2011: President of the Graduate Student Organization for the 
Marshall University Biomedical Sciences Program. 
 
March 2010:   Volunteer at second annual Brain Expo at Marshall 
University.  Presented information and hands-on activity to 
area school children about vision as part of International 
Brain Awareness Week. 
 
May 2009-April2010: Vice-President of the Graduate Student Organization for the 
Marshall University Biomedical Sciences Program.  Duties 
include attending Graduate Studies Committee meeting to 
act as a liaison between faculty and fellow graduate students 
and assisted the President in the decision making and 
planning of various fundraising events. 
 
March 2009: Volunteer at first annual Brain Expo at Marshall University.  
Presented information and hands-on activity to area school 
children about the different parts of the brain as part of 
International Brain Awareness Week. 
 
 
Awards 
April 2010:  Recipient of the NASA West Virginia Space Grant Consortium for the 
proposed project entitled “The Potential Role of Vascular Endothelial 
Growth Factor (VEGF) in the Diabetic Brain Microvasculature.”  
Monetary Amount:  $12,000. 
June 2010:  Recipient of Registration Fee Waiver for the Gordon-Kenan Research  
       Seminar on Barriers of the CNS, Colby-Sawyer College, New London, NH. 
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June 2010:  Recipient of Travel Award for the Gordon Research Conference on Barriers  
       of the CNS, Colby-Sawyer College, New London, NH. 
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